Podcasts about Aromatase

Sleep isn't just rest - it's your body's most extraordinary healing mechanism. Every night, regardless of what you've eaten or how you've treated your physical vessel during the day, your cells engage in a remarkable process of renewal and forgiveness. Unlike cars, phones, and other machines that deteriorate over time, we humans have this built-in reset button that allows us to wake up renewed and restored.This podcast delves deep into the contrast between pharmaceutical approaches to hormone-related conditions and nature's more balanced alternatives. Aromatase inhibitors like letrozole, commonly prescribed to postmenopausal women with hormone-sensitive cancers, come with a staggering array of side effects affecting joints, bones, cognition, and mood. Meanwhile, research from the Journal of Biological Chemistry shows that phytoestrogens from plants like soy selectively trigger beneficial estrogen receptor pathways while avoiding harmful ones - a level of sophisticated targeting that pharmaceutical options can't match.The discussion challenges numerous health misconceptions propagated by mainstream medicine. Did you know that Japanese people consuming traditional diets take in over 100 times more iodine than the FDA recommends, yet have lower cancer rates and longer lifespans? Or that wearing bras 24/7 restricts lymphatic flow and correlates with increased breast cancer risk? These inconvenient truths highlight how conventional medical wisdom often ignores or contradicts available research.Perhaps most powerful is the paradigm shift offered regarding chronic disease. Rather than viewing conditions like cancer as invaders to be bombed with aggressive treatments, we're encouraged to understand them as adaptive responses by cells to unfavorable conditions. The solution lies not in warfare but in restoration - creating an inSend us a text Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Support the showThis episode features answers to health and cancer-related questions from Dr. Lodi's social media livestream on Jan. 19th, 2025Join Dr. Lodi's FREE Q&A livestreams every Sunday on Facebook, Instagram, and Tiktok (@drthomaslodi) and listen to the replays here.Submit your question for next Sunday's Q&A Livestream here:https://drlodi.com/live/Facebookhttps://www.facebook.com/DrThomasLodi/Instagramhttps://www.instagram.com/drthomaslodi/ Join Dr. Lodi's Inner Circle membership and unlock exclusive access to webinars, healthy recipes, e-books, educational videos, live Zoom Q&A sessions with Dr. Lodi, plus fresh content every month. Elevate your healing journey today by visiting drlodi.com and use the coupon code podcast (all lowercase: P-O-D-C-A-S-T) for 30% off your first month on any membership option. Learn to Thrive with ADHD Podcast Welcome to the Learn to Thrive with ADHD Podcast. This is the show for you if you're... Listen on: Apple Podcasts Spotify Join Dr. Lodi's informative FREE Livestreams...

Because of breast cancer, fear of cancer recurrence is a permanent part of my life. I continue taking tamoxifen to reduce my risk of the cancer coming back. In this episode I share my thoughts on the good quality of life I have while taking tamoxifen. I value my strong body and theimited side-effects I have now. I also value a life with the lowest possible risk of breast cancer recurrence. I look forward to discussing what it might mean to switch to an aromatase inhibitor, in terms of further lowering the risk of recurrence and potentially experiencing more serious side-effects, with my oncologist  On more than one occasion, the oncologist has brought up endocrine therapy and the possibility of switching from tamoxifen to an aromatase inhibitor “in the future”.  Even my breast surgeon provided a quick plug for the lower risk of recurrence associated with taking aromatase inhibitors, compared to tamoxifen, without highlighting any of the aromatase inhibitor side-effects.  Determining what might be the best endocrine therapy for me to prevent recurrence is not going to be easy.  So far, neither doctor has done a deep dive into the different side-effects among the two drugs or what a change might do to overall health and quality of life.   Thank you for listening to my story! If you'd like to be the first to receive updates and exclusive content from the upcoming Breast Cancer Life newsletter, please email me at connect@breastcancerlife.org. I'd love to have you on the list! LET'S CONNECT: connect@breastcancerlife.org  Follow us on Pinterest 

In this episode of Better Than Before Breast Cancer, we're talking about the crucial role of magnesium in breast cancer recovery, metabolic health, and overall well-being What You'll Learn in This Episode:✅ Why magnesium is vital for breast cancer survivors and how it supports healing✅ How chemotherapy, aromatase inhibitors, and stress can deplete magnesium levels✅ The best types of magnesium supplements (and which one is right for you!)✅ How to get enough magnesium through diet with whole, nutrient-dense foods✅ Signs of magnesium deficiency and how to test your levels✅ How magnesium impacts inflammation, bone density, and hormone balance Download Your Free Resources:

In today's episode we're diving into a question I hear all the time: “Why do I need to take aromatase inhibitors if I'm post-menopausal? Isn't my body done making estrogen?” If you've wondered the same thing, you're not alone! We'll explore how your body still produces small amounts of estrogen even after menopause, and why this matters for breast cancer survivors. I'll explain where post-menopausal estrogen comes from—hint: it's not just your ovaries—and how lifestyle factors can support your body's hormone balance. You'll also hear why aromatase inhibitors play an important role in preventing recurrence, but we won't avoid discussing their risks, either. We're also diving into something that might surprise you—a genetic variation that can make one aromatase inhibitor less effective in some women. This genetic factor can impact how your body metabolizes the drug, which you want to hear about! I'm excited for you to tune in to this episode, whether you're currently on aromatase inhibitors, considering them, or just curious about how your body works post-menopause. I'll cover all of this and more to help you make the best choices for your health and healing after breast cancer. Don't miss it! Referred to in this episode: Work with Laura   Follow me on Social Media:  Facebook Instagram Pinterest YouTube

The first episode of the HRT after breast cancer series features oncologist Dr. Leila Agrawal, who discusses the evidence, studies, and trials regarding HRT for breast cancer patients.Dr. Laila Agrawal is a medical oncologist and haematologist specialising in treating breast cancer patients. She is involved in research and clinical trials and she strives to get to know every patient and learn what is important in their lives, from their families to their goals, and how that plays into important decisions about their health.This mini-series explores hormone replacement therapy (HRT) after breast cancer, a controversial and emotive subject. The conversation focuses on the further understanding of risks and benefits of HRT (hormone replacement therapy) or also MHT (menopause hormone therapy), the emotional impact on patients, and the different views among medical professionals. The goal is to provide understanding for patients seeking HRT after breast cancer and insight for doctors on how to move forward without robust evidence. Dani Binnington, host of the Menopause And Cancer podcast, and founder of the not-for-profit organisation Menopause And Cancer has spoken to hundreds of women who feel like they are in a void and have nowhere to turn to in discussing this difficult topic. Welcome to our HRT after breast cancer series.In this episode we discuss:The role of hormone-blocking medications such as tamoxifen and aromatase inhibitors for breast cancer survivors.Dr. Agrawal discusses many studies on HRT after breast cancer, including the The Habits study which showed an increased risk of recurrence in the HRT group, leading to the trial being stopped early.She goes on to explain The Stockholm study which did not show an increased risk of recurrence.Dr. Agrawal explains other studies, including observational studies that looked at the use of hormone replacement therapy after breast cancer and explains the outcome of meta-analysis for different types of breast cancers. We discuss what these study results mean for different types of cancers, such as triple-negative breast cancer. Dr. Agrawal discusses the difference between absolute risk and relative risk is and why this is important when interpreting data.Additional research is needed to determine the safety and efficacy of HRT in breast cancer survivors.Episode Highlights: 00:00 Intro.04:19 Understanding patient perspectives and ethical medical decisions.08:10 Different types of breast cancer treatment options.09:52 Aromatase inhibitors used to treat breast cancer.17:01 Breast cancer trial halted due to risk.25:05 Stockholm Study.37:14 Interpreting risk reduction impact of treatments accurately.48:04 Data on tamoxifen and HRT remains inconclusive.53:25 Understanding and quantifying medical risks for patients.Connect with us:For more information and resources visit our website: www.menopauseandcancer.org Or follow us on Instagram @menopause_and_cancerJoin our Facebook group: www.facebook.com/groups/menopauseandcancerchathub

In this episode of The Metabolic Classroom, Dr. Ben Bikman explores the metabolic effects of estrogens, particularly their role in glucose metabolism.Estrogens, mainly produced in the gonads, play a crucial role in regulating blood glucose by enhancing insulin sensitivity. Dr. Bikman explained that estrogens improve insulin signaling through pathways such as PI3 kinase and AKT, which are essential for glucose uptake in muscle and fat tissues. Additionally, estrogens activate AMP-activated protein kinase (AMPK), further promoting glucose uptake and maintaining healthy blood glucose levels.Estrogens also suppress glucose production in the liver by inhibiting key enzymes involved in gluconeogenesis, helping to prevent excess glucose release into the bloodstream. In contrast, progesterone decreases insulin sensitivity and promotes insulin resistance, counteracting some of estrogen's beneficial effects. This hormonal interplay affects glucose metabolism during the ovarian cycle, with estrogen-dominant phases being more favorable for glucose control.During menopause, the significant drop in estrogen levels leads to increased insulin resistance and shifts in fat storage, often resulting in more central fat accumulation. While hormone replacement therapy (HRT) can mitigate some of these changes, it comes with risks that need careful consideration. Ben emphasizes the significant role of estrogens in glucose metabolism and their broader impact on metabolic health, especially in women.https://www.insuliniq.com 01:19 - Overview of Estrogens and Progesterone02:20 - Cholesterol as the Precursor to Sex Hormones03:34 - The Role of Aromatase in Estrogen Production04:32 - Understanding the Family of Estrogens05:56 - Estrogens and Glucose Metabolism: Key Signaling Pathways06:54 - Insulin Signaling Pathway Overview08:57 - How Estrogens Enhance Insulin Sensitivity10:04 - The Role of AMPK in Glucose Uptake12:11 - Estrogens' Dual Mechanism in Regulating Glucose Levels13:18 - The Impact of Estrogens on Liver Glucose Production15:33 - Estrogens' Role in Suppressing Gluconeogenesis17:07 - Why Women Have Lower Risk of Type 2 Diabetes19:28 - Metabolic Effects During the Ovarian Cycle21:54 - Progesterone's Influence on Insulin Resistance and Fat Storage25:16 - The Shift in Fat Storage Patterns Post-Menopause26:16 - Hormone Replacement Therapy: Metabolic ConsiderationsPI3K activation leads to the phosphorylation of Akt, a key protein in glucose metabolism, which promotes the translocation of GLUT4 (glucose transporter type 4) to the cell membrane, facilitating glucose uptake into muscle and adipose tissue: https://www.sciencedirect.com/science/article/pii/S155041311930138X?via%3Dihub AMPK acts as an energy sensor and helps maintain cellular energy balance, which is crucial in regulating glucose and lipid metabolism: https://link.springer.com/article/10.1007/s12013-015-0521-z Progesterone increases blood glucose levels by enhancing hepatic gluconeogenesis. This effect is mediated by the progesterone receptor membrane component 1 (PGRMC1) in the liver, which activates gluconeogenesis pathways, leading to increased glucose production, especially under conditions of insulin resistance: https://www.nature.com/articles/s41598-020-73330-7 Hosted on Acast. See acast.com/privacy for more information.

If you're struggling to get out of bed, feeling moody, depressed, or suffer from a low libido, this episode is for you. Whether you're male or female, you can benefit from testosterone. Jay Campbell is on a mission to help you discover the benefits of the testosterone optimization therapy. Today we dive into the Testosterone Optimization Bible and the do's and don'ts of testosterone. Episode brought to you by the world's best organic sheets. Code: DEELEY15 Jay Campbell is a four-time international best selling author, men's physique champion and founder of the Jay Campbell Brand and Podcast. 5:41: What's driving low testosterone? 6:00: Wait, Tesla's are bad for your health? 9:50: The average doctor that prescribes therapeutic hormones to people has no idea what they're doing 10:34: What's the ideal age to start TRT? (Best solution: get your FREE testosterone tested, but people as young as 17 can benefit from TRT if they have low levels) 12:51: Would you consider Clomid over TRT? (Clomiphene) 15:13: Difference between free and total testosterone 16:44: Your Doctor tells you you're in 'the normal range' but you don't feel normal... 19:27: Most men need to be between 35-55 of Free Testosterone to feel amazing 20:19: How to feel amazing as a woman approaching or over 40 20:54: Thyroid health must be optimal 22:50: Symptoms of low testosterone in both men and women 24:57: Benefits from taking TRT/Testosterone Replacement Therapy 27:06: TRT can act like Modafinil or Tesofenzine 27:54: Three different delivery systems to take TRT (oral, injectables, and creams) 30:10: You want to mimic your body's natural production 32:59: Best location to use testosterone cream which as the most bioavailability: scrotum (and clitoral region for women) 34:26: Does your body stop making testosterone if you start taking it therapeutically? 36:20: Top 10 questions to ask your Doctor about therapeutic testosterone PDF 36:29: The truth about pellets 39:53: Pellets are the most expensive delivery system 40:06: How do you know if you're a high excreter? 41:21: TestosteroneAddiction.com 42:37: The difference between a pill and a poison is the dosage 42:56: What dosage should we be taking? 43:14: Men; injectable: 150 - 200 milligrams a week (or 2 - 3 clicks if using cream) 45:17: Women; oral: .75 - 2.5 milligrams 47:43: Dr. Scott Howell and androgens 49:42: Aromatase inhibitor supresses estrogen 52:03: Dr. Rob Kominiarek 53:07: Just say no to statins 59:24: If you begin taking testosterone, do you need to take it for the rest of your life? 1:00:07: Testosterone boosters on TV (do they work?) 1:03:13: Can a man over 70 safely start testosterone? 1:04:13: Can testosterone re-grow your hair? 1:05:30: Auxano (use with caution as it contains a toxic PUFA: grapeseed oil) 1:05:41: Folitin to regrow hair 1:05:56: Hair loss is caused by blood flow restriction to the scalp 1:08:45: Fasting is the greatest, again, cellular fumigator 1:12:05: Regenevive & Regeneburn Where to find Jay: Website Instagram Amazon

Download The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

Watch Here : https://www.youtube.com/watch?v=2JPZ2icOpg0 Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

ResourcesBronson R. and Kruljac I, Butorac D, Vrkljan M. and Legro RS, Zhang H; Eunice Kennedy Shriver NICHD Reproductive Medicine Network. Letrozole or clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(15):1463-1464. doi:10.1056/NEJMc1409550Centers for Disease Control and Prevention. PCOS (Polycystic Ovary Syndrome) and Diabetes. https://www.cdc.gov/diabetes/basics/pcos.html. Accessed April 21, 2024.Franik S, Kremer JA, Nelen WL, Farquhar C. Aromatase inhibitors for subfertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2014;(2):CD010287. Published 2014 Feb 24. doi:10.1002/14651858.CD010287.pub2Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022;9(9):CD010287. Published 2022 Sep 27. doi:10.1002/14651858.CD010287.pub4Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome [published correction appears in N Engl J Med. 2014 Oct 9;317(15):1465]. N Engl J Med. 2014;371(2):119-129. doi:10.1056/NEJMoa1313517Legro RS, Diamond MP, Coutifaris C, et al. Pregnancy registry: three-year follow-up of children conceived from letrozole, clomiphene, or gonadotropins. Fertil Steril. 2020;113(5):1005-1013. doi:10.1016/j.fertnstert.2019.12.023Palomba S, Santagni S, Falbo A, La Sala GB. Complications and challenges associated with polycystic ovary syndrome: current perspectives. Int J Womens Health. 2015;7:745-763https://doi.org/10.2147/IJWH.S70314World Health Organization. Polycystic Ovary Syndrome. World Health Organization; 2023. Accessed April 21, 2024. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndromeZhang H. Pregnancy in Polycystic Ovary Syndrome II (PPCOSII). ClinicalTrials.gov identifier: NCT00719186 . Updated June 14, 2018. Accessed April 20, 2020. https://classic.clinicaltrials.gov/ct2/show/NCT00719186

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Aromatase Deficiency⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Reproductive section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

Chris Masterjohn's guide on MB: https://chrismasterjohnphd.substack.com/p/the-guide-to-methylene-blue

Summary Dr. Caoimhe Hartley discusses perimenopause, menopause, and the symptoms women may experience during this time. She explains the impact of hormonal fluctuations on endometriosis and the importance of managing symptoms during perimenopause. Dr. Hartley also explores various treatment options for perimenopause and postmenopause, including hormone replacement therapy (HRT) and the use of testosterone. She emphasises the need for individualised care and risk assessment when considering HRT. Additionally, Dr. Hartley highlights the importance of lifestyle factors in managing menopausal symptoms and reducing overall health risks. This conversation covers various topics related to hormone replacement therapy (HRT) and the management of menopausal symptoms. It explores individualised approaches to HRT, the importance of long consultations and patient advocacy, options for managing menopausal bleeding, non-hormonal medications for heavy bleeding, different hormonal options for bleeding control, the use of Tibolone as an alternative hormone therapy, the safety of vaginal oestrogens in breast cancer patients, and the myth of hormone balancing. Takeaways Hormone replacement therapy (HRT) should be individualised based on a person's symptoms, risk factors, and preferences. It is not a one-size-fits-all approach. Long consultations and patient advocacy are crucial in providing comprehensive care for menopausal patients. Patients should be well-informed and actively involved in their treatment decisions. There are various options for managing pre and perimenopausal bleeding, including non-hormonal medications like tranexamic acid, as well as hormonal options. Tibolone is a synthetic steroid that can be used as an alternative hormone therapy. It has similar benefits to other forms of HRT and is considered safe for most women. It was studied as addback HRT for use with GnRHa like Zoladex. Aromatase inhibitors are commonly used in post-breast cancer treatments and infertility. They can be effective but may cause significant side effects. Some patients with endometriosis have used them for symptom control. Vaginal oestrogens are safe and effective for managing vaginal dryness and other genitourinary symptoms in women. They do not increase the risk of breast cancer. Resources Dr Caoimhe Hartley - Menopause Health https://www.menopausehealth.ie/ Chapters 00:00 Introduction and Background 03:32 Perimenopause and Menopause 06:50 Perimenopausal Symptoms and Endometriosis 15:06 Treatment Options for Perimenopause and Postmenopause 20:17 Managing Symptoms in Hysterectomy Patients 22:48 The Use of Testosterone in Menopause 27:44 Alternative Options for Women Not Taking HRT 34:51 Risks and Side Effects of HRT 40:23 Individualised Risk Assessment 41:13 Individualised Hormone Replacement Therapy (HRT) 42:02 Long Consultations and Patient Advocacy 43:14 Managing Menopausal Bleeding 44:19 Non-Hormonal Medications for Heavy Bleeding 44:49 Hormonal Options for Bleeding Control 45:46 Tibolone as an Alternative Hormone Therapy 48:36 Aromatase Inhibitors in Endometriosis Treatment 50:53 Vaginal Oestrogens and Breast Cancer 54:46 The Myth of Hormone Balancing

Damiana: https://amzn.to/3PPY0JR➕ Double testosterone masterclass: https://testonation.gumroad.com/l/testosteronemasterclass/MC

Commentary by Dr Hidehira Fukaya

Joint pain is common, but that doesn't mean you have to suffer! There are so many natural remedies to control and relieve the discomfort. Whether you are preventing joint pain during treatment or you have ongoing arthritis-type pain, Tina & Leah talk about ways to find relief. We even tackle the tough-to-treat joint pain from aromatase inhibitors (yes, there are things you can do!). Sometimes, the answer is already in your kitchen!Links to prior episodes we mention:Turmeric Brain Fog Sammy Peterson, RD, CSO Rebecca Katz- nutrition, recipes, etc.- her website and her cookbooks. Aromatase Inhibitors and Vitamin D in your blood.Exercise to reduce the joint pain from aromatase inhibitors.Community acupuncture can keep your cost for acupuncture way down.Support the showShare this podcast with someone you think would like it!https://www.thecancerpod.com Have an idea or question? Email us: thecancerpod@gmail.comJoin our growing community, we are @TheCancerPod on: Instagram Twitter Facebook LinkedIn We appreciate your support! THANK YOU!

Men! Listen up! This one's for you. (Ladies, this will help you too!)Optimizing your metabolic health will enhance testosterone production, utilization and overall well-being. Join my discussion with Patrick Scheel, a registered dietitian and nutritionist with NutriSense Continuous Glucose Monitor, as we delve into this critical question.Metabolic health and its crucial link with blood sugar regulation, especially in times of stress, is a key highlight of our conversation with Patrick. Backed by his clinical experience from the ICU, he showcases how products like NutriSense Continuous Glucose Monitor can provide valuable assistance in achieving optimal health.Check Out Patrick Scheel and NutriSense* Listeners of The Dr. Tyna Show get $30 OFF when they use code DRTYNA at check out and follow THIS LINK: nutrisense.io/drtyna* Patrick ScheelOn this episode we cover: 13:00 Male testosterone and hormonal imbalance 23:27 - Aromatase and sex hormone binding globulin and its relationship to estrogen and testosterone31:00 why men wanna get rid of your gut 33:05 - Low carb diets and sex hormone binding globulin 45:00 why men need to do deadlifts and squats50:20 - Stress: What is It Doing to Our Metabolic Health?57:50 - What is a good timeframe to use a Continuous Glucose Monitor1:03 - The Key is Sustainability and ConsistencySponsored By:ALITURA NATURALS SKIN CAREUse Code DRTYNA for 20% offBiOptimizers Head to bioptimizers.com/drtyna and use promo code DRTYNA during their Mega Black Friday SaleLMNTGet 8 FREE packs with any order at drinkLMNT.com/drtynaNutrisense Continuous Glucose Monitors (CGM)Listeners of The Dr. Tyna Show get $30 OFF when they use code DRTYNA at check out and follow THIS LINK: nutrisense.io/drtynaHead to www.Drtyna.com for the following offers:Grab my FREE GUIDE to Assess Your Metabolic Health.Check out my Metabolic Revamp Toolkit for a deeper dive.Grab My Winter Crud Cheat Sheet Now! Click Here!Further Listening:EP. 94: For the Men: Master Your Testosterone | Solo EpisodeEP. 95: Women Need Testosterone Too | Solo Episode Disclaimer: Information provided in this blog/podcast is for informational purposes only. However, this information is NOT intended as a substitute for the advice provided by your physician or other healthcare professional, or any information contained on or in any product. Do not use the information provided in this blog/podcast for diagnosing or treating a health problem or disease, or prescribing medication or other treatment. Always speak with your physician or other healthcare professional before taking any medication or nutritional, herbal or other supplement, or using any treatment for a health problem. If you have or suspect that you have a medical problem, contact your health care provider promptly. Do not disregard professional medical advice or delay in seeking professional advice because of something you have read in this blog/podcast. Information provided in this blog/podcast and the use of any products or services related to this blog/podcast by you does not create a doctor-patient relationship between you and Dr. Tyna Moore. Information and statements regarding dietary supplements have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent ANY disease. Get full access to Dr. Tyna Show Podcast & Censorship-Free Blog at drtyna.substack.com/subscribe

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter We discuss: Derek's interest in weightlifting and experimentation with anabolic steroids at a young age [3:15]; Derek's experience acquiring steroids from underground labs and the potential long-term fertility concerns early in his bodybuilding career [12:00]; The backstory on More Plates, More Dates and Derek's unique ability to blend scientific knowledge with personal observation [17:00]; Growth hormone – from extreme use-cases to the more typical – and the misconception that it's the “elixir of life” [21:30]; Growth hormone 101: definition, where it comes from, and the challenges of measuring it [28:45]; Does exogenous growth hormone compromise one's ability to make endogenous growth hormone? [40:00]; The use of growth hormone in restoration of tissue during periods of healing [42:00]; Growth hormone-releasing peptides to increase endogenous GH: various peptides, risks, benefits, and comparison to exogenous growth hormone [48:45]; The role of growth hormone in building muscle and burning fat, as well as its effects on sleep and daytime lethargy [1:02:30]; The evolution of drug use in the sport of bodybuilding [1:10:30]; What explains the protruding abdomens on some bodybuilders and athletes? [1:20:30]; Death of bodybuilders [1:26:00]; The complex interplay of hormones, and the conversion of testosterone into metabolites like DHT and estrogen [1:33:45]; Post-finasteride syndrome and how Derek successfully treated his hair loss [1:43:15]; Testosterone replacement therapy: compelling use-cases, side effects, and optimal dosing schedules [1:57:15]; Aromatase inhibitors to suppress estrogen, and the misconceptions around estrogen in men [2:16:00]; Other hormones beyond testosterone for male sex hormone replacement [2:21:00]; The history of anabolic compounds, and the differing effects of various anabolic testosterone derivatives and related drugs [2:24:30]; Use of SARMs by bodybuilders [2:29:45]; Anabolic steroid and testosterone regimens of professional bodybuilders and the downstream consequences [2:36:15]; The challenge of accurate hormone testing in the presence of anabolic steroids and supplements [2:44:45]; The use of Clomid, hCG, and enclomiphene [2:47:15]; Concerns about fertility: comparing the use of testosterone and hCG [3:00:30]; The use of BPC-157 peptide for healing injuries [3:12:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-023-00237-4. All conflicts of interest can be found online.   Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Testo-Launch course - everything you need to know about testosterone optimization

The All Things Testosterone podcast is a product of the TRT Community. We are the world's largest online support system for men and women undergoing Testosterone Replacement Therapy, or "Patients Helping Patients." Join our FREE Facebook group below!   On today's episode we discussed the following:   Aromatase inhibitors HCG Penile Sensitivity TRT Driven Adultry   Thanks for listening! Please rate, review, subscribe and join our FREE Facebook community below!   TRT Community Private Facebook Group Take a Free Glucose Quiz Find a TRT Doctor

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In September 2022, ASCO and the Society for Integrative Oncology, or SIO, published a joint guideline on using integrative therapies to manage pain in people with cancer. Integrative therapies are treatments and techniques used in addition to standard cancer treatment to help people cope with the side effects of cancer, including cancer-related pain. In this podcast, Dr. Richard Lee talks to the guideline panel co-chair, Dr. Jun Mao, about these guideline recommendations. They discuss why the guideline was created and the different types of integrative therapies included in these recommendations, including acupuncture, reflexology and acupressure, hypnosis, massage, yoga, guided imagery and progressive muscle relaxation, and music therapy. Dr. Lee is a clinical professor in the Departments of Supportive Care Medicine and Medical Oncology at City of Hope Comprehensive Cancer Center and serves as the medical director of the Integrative Medicine Program. Dr. Lee is also the 2023 Cancer.Net Associate Editor for Palliative Care. Dr. Mao is chief of the Integrative Medicine Service at Memorial Sloan Kettering Cancer Center and holds the Laurance S. Rockefeller Chair in Integrative Medicine at the institution. View disclosures for Dr. Lee and Dr. Mao at Cancer.Net. Dr. Lee: My name is Richard Lee. I'm a clinical professor here at City of Hope Cancer Center. I'm in the Departments of Supportive Care Medicine and Medical Oncology and medical director for the Integrative Medicine Program. I'm honored to be accompanied today by Dr. Jun Mao. He's the chief of the Integrative Medicine Service at Memorial Sloan Kettering and holds the Laurance S. Rockefeller Chair in Integrative Medicine. So we're going to talk about the joint SIO-ASCO guidelines that recently came out in the Journal of Clinical Oncology looking at integrative approaches to cancer pain. And so let me first ask you, Jun, could you talk about what is a clinical practice guideline, and how does it help guide cancer care? Dr. Mao: The clinical practice guideline is a process bringing multidisciplinary experts to look at the evidence from randomized clinical trials or systematic reviews and meta-analysis and to really evaluate the level of the evidence from research and clinical trials, and also incorporate our clinical expertise, consideration for the benefit and risk. Then, making a set of recommendations for doctors and nurses, health care providers to make informed decisions for patients. Dr. Lee: Great. And tell us more, what is integrative medicine for those patients who may not have a full understanding what this field is about? Jun Mao: So integrative medicine is a complex term. Originally, a lot of people may have heard that term of “alternative medicine” or “complementary medicine.” So those terms are referring to using things like herbs or shamanism instead of a conventional cancer treatment. So recognizing the needs of patients who want to explore alternative ways to help them to cope with cancer, and the importance of adhering to conventional surgery, radiation therapy, chemotherapy. So the field of integrative medicine has emerged. Integrative medicine is a field that is based on evidence and acknowledge the patient's wishes to carefully incorporate evidence-based lifestyle interventions, mind-body treatments, and consider for natural products and herbal medicine in a safe and effective way to improve patients' physical, emotional, and spiritual well-being. Also, part of the goal of integrative medicine is to really engage the patient as an active participant to prevent cancer and to really engage in their own care during and beyond their cancer treatment. Dr. Lee: And for patients who are new to this concept of integrative medicine or integrative therapies, why is it important for us to study this for cancer care? Dr. Mao: Richard, this is really important because often when a person gets cancer, you get friends and family who really want to be helpful who say, “Do this, try that, use this herb, or this supplement has been used by that.” So there's a lot of anecdote. There's a lot of sort of people just want to be helpful. But in actuality, some of the treatments, without carefully considering actual evidence and potential risks of drug herbal interaction, can induce harm, not only increase the toxicity of the cancer treatment, but may even shorten the lives of cancer patients. Therefore, we often tell patients don't use these treatments as alternative, but to use in an integrated way. And doing research is going to be helpful to understand in what setting for what condition or symptoms. These are helpful, not helpful, are they safe or unsafe? Dr. Lee: That's really important. That's great to see the research coming along. And so let's talk about ASCO, the American Society for Clinical Oncology, which is the world's leading and largest professional organization for oncologists, as well as Society for Integrative Oncology, SIO. You know, how did they come together to produce this joint guideline on integrative medicine and pain management? Dr. Mao: So, as you know, ASCO is a world-leading conventional oncology society. It's a multi-discipline, you know, surgeons, medical oncologists, radiation oncologists, a lot of psychosocial supportive care folks are part of this society. Society for Integrative Oncology is a relatively new society, but this year we're celebrating 20th year, so it's not so new anymore. You know, a lot of very passionate physicians, nurses, nutritionists, social workers, we joined together to really help to advocate for evidence-based integrative medicine in the context of care delivery. SIO brings that expertise together with ASCO to formulate a set of guidelines that can be readily implemented into the care setting to help patients and families to deal with pain, a very common and disturbing side effect for cancer and cancer treatment. Dr. Lee: It's so great to see 2 leading organizations come together to put these guidelines together. So let's jump into the guidelines a little bit, and one of the areas that they covered is acupuncture. So can you let us know and let patients know what is acupuncture, and what types of cancer-related pain has it been shown to be helpful? Dr. Mao: Acupuncture is a type of therapy that originated from the traditional Chinese medicine. It has been documented over 2,500 years ago. So the way acupuncture works clinically is putting very thin, sterile needles in specific locations of the body to help address symptoms, promote a sense of relaxation and wellness. Often, you need a series between 6 to 10 treatments. I always tell patients it's almost like a physical therapy. You need a few treatments to see the benefit. In animal research, there has been a documented mechanism that acupuncture may help your brain to release endogenous neurotransmitters, like endogenous opiates, serotonin, or dopamine, as a result to reduce pain, increase a sense of relaxation, well-being. So the ASCO-SIO Joint Clinical Guideline looked at clinical trials, found pretty strong evidence that acupuncture can be used for a type of joint pain that is very common in women with breast cancer taking aromatase inhibitors. Aromatase inhibitors are a class of drug that drop the estrogen level in women with breast cancer as a result of preventing the breast cancer from spreading. Unfortunately, about 50% of women do develop very diffuse joint pain. A lot of time it is in the low back and knees and makes a lot of patients stop this life-saving drug. The committee feels strongly like acupuncture should be recommended as one of the options to treat aromatase inhibitor-related joint pain. In other areas, not as strong, but also in general cancer-related joint pain and musculoskeletal pain. And there are also some weak evidence on acupuncture can be helpful for chemotherapy-induced peripheral neuropathy, as well as to be used in post-surgical related pain. So those are the recommendations we would tell a patient who experienced those pains to try acupuncture. Dr. Lee: So Jun, you mentioned about the different recommendations around acupuncture, and you're talking a little bit about levels of evidence. Could you explain to patients what you mean by the levels of evidence and the types of recommendations that were put forward by ASCO and SIO? Dr. Mao: So when experts review evidence from clinical trials, if you have several large clinical trials producing very consistent findings that a therapy is beneficial with very low risk, that will give you a high level, strong quality of evidence with strong recommendation. Unfortunately, in the field of integrative medicine, often there's a lack of funding for this type of research. So what you do see is there are maybe only 1 trial showing that it's very beneficial and maybe there are some smaller trials to show some signal, then we will give an intermediate quality of evidence and moderate strength of recommendation. And then you have therapies that are being used by patients, but there's very little trials or the trials, the sample size are very small. Sample size means how many patients participate. Then you see some promising signals overall, but it's kind of, you know, we don't have a strong confidence in the result. That's where we give low quality of evidence and weak strength of recommendation. Dr. Lee: That's really helpful and it's, I think, important since integrative medicine is really based on evidence-based approaches that we are looking at the levels of evidence. So thank you for explaining that. Let's move on to some other therapies that were mentioned within the guidelines. You talk about reflexology and acupressure. Can you talk about what these types of therapies are and what have they been shown to help? Dr. Mao: So reflexology acupressure, so this is a very similar sort of a principle of treatment, but instead of putting needles, it's actually a therapist will put hands on or teach the patient to press specific acupuncture or pressure points as a result to reduce pain or induce relaxation. So here is where you see some intermediate quality of evidence with moderate strength of recommendation for general cancer pain or musculoskeletal pain as the patient is receiving treatment. One common area you would see that is sometimes when a patient's getting chemotherapy, they will have these muscle aches and joint pain. It's not long lasting, but it's very annoying for a number of days. So in those settings, you can try that.   Dr. Lee: So for patients who might have a needle phobia and are very hesitant, would it be reasonable for them to think about reflexology and acupressure as another modality? Dr. Mao: Oh, absolutely. And also I want to clarify reflexology often is done on the feet. So a lot of patients may not necessarily like general massage. Some people love it, but other people just don't want people to touch their whole body. Then the reflexology just focusing on massaging the feet or lower legs can be a really good option. Dr. Lee: Yeah, great to see there are options for patients, depending on their preferences. Let's move on to another therapy in the guidelines that mention hypnosis. And so a lot of patients may not be familiar with what is hypnosis and where can that be applied for patients with cancer? Dr. Mao: Hypnosis is really about changing a state of awareness and a sense of increased relaxation that often allows for improved focus or concentration. But when you talk about hypnosis in a health care setting, it is often done by a provider with verbal repetition, provided with some mental images. Often during hypnosis, patients can be taken to a different mental place and feel a sense of relaxation and calm. And where you see some evidence is actually for procedural pain. This is derived from a large, randomized trial for biopsy, as well as some interventional procedure showing that hypnosis produces benefit for pain reduction, more of acute pain relief. Again, it makes sense physiologically, right? You take your mind and consciousness to a different place rather than focus on the procedure and pain. So this is where we give intermediate quality of evidence and moderate strengths of recommendation. Dr. Lee: Mm-hmm, good. And let's talk a little bit more about massage. You mentioned that a little bit when you were talking about reflexology. Can you tell us about what situations might massage be helpful for the patients? Dr. Mao: So massage, many people know is really applying pressure in a specific body area. And certainly, for oncology massage, people need to have some specific training to be safe, make sure people don't put pressure in where the tumor is or where there may be fracture risk for bone metastasis as well as in where their medical port is. So I would advise patients work with people who have specialized oncology training. With that said, I think we find really good evidence, particularly in the area of use in palliative care. So there was a large trial with over 300 people randomized to either massage or just gentle touch. Massage reduced pain and improved mental health. So I would say massage to be utilized in patients living with advanced cancer or for patients in a hospice setting can be a really beneficial tool. Where there is a slightly, sort of a weaker evidence I would say, is in the area of a general musculoskeletal pain as the patient is experiencing treatment or in survivorship. There, we give a low quality of evidence, but a moderate strength of recommendation. The reason we give a moderate strength of evidence is the risk is really minimal, right? Like even though we don't have a good amount of research, but even say massage produces some temporary relief, it can still be very beneficial for the patients. Dr. Lee: And let's shift gears a little bit to something called yoga, which many of us may know from your local gym. Can you talk a little bit about yoga and what does that mean for patients who have cancer, and how can that help with cancer-related pain? Dr. Mao: Yoga, as many of you know, originated from India, maybe even as old as 5,000 years ago. So yoga practices, it really combines breath work with meditative work with posture, right, specific postures. So often we know in routine, just health industry, yoga can be really good for physical balance, for flexibility, for induced sense of relaxation. So less is known about the use of that for pain management. So there were some small studies to show that yoga showed really good potential benefit in addressing aromatase inhibitor-related joint pain. The reason we give it a low quality of evidence and weak strength of recommendation is because the research is not as developed in this area. Also, in one of the trials, the pain was the secondary outcome rather than the primary outcome. So it was not the outcome they hypothesized to find, although they did find some benefits. So with that, we do feel like given how yoga is relatively low risk, it's very accessible. So it could be considered for women with breast cancer experiencing aromatase inhibitor-related joint pain. Dr. Lee: And then, Dr. Mao, could you comment a little bit about--there's so many different styles of yoga. Some of them are very physical, like the kind of hot yoga versus other styles might be more gentle. Can you comment a little bit about that and in terms of what style patients might want to consider? Dr. Mao: There's also a national organization to help to train yoga instructors to work with cancer survivors. So as you look out for those programs, you should really look at people who have those experiences. And I would say most of the studies use more of a hatha type of, more gentle yoga rather than the probably rigorous sort of yoga. Particularly, I would say for women with breast cancer on hormonal drugs, there's higher risk for osteoporosis. So it's important to consider the risks. And I would work with highly experienced instructors rather than trying very risky moves that potentially can cause musculoskeletal injuries or fractures. Dr. Lee: Good things to keep in mind as you think about these different therapies. Let's focus more on these kinds of what some consider mind-body techniques: guided imagery, progressive muscle relaxation. Can you talk about these types of therapies, and can the 2 techniques be used in combination to help with cancer pain? Dr. Mao: So these are very common techniques in the realm of mind-body and relaxation technique. Often you will listen to words and the words will guide you to imagine you're on a beach or hiking in the green meadows. And often there's nice music along with the verbal suggestions. And with progressive muscle relaxation, sometimes we'll ask you to squeeze certain muscle and then release, squeeze and release. By doing that, it also causes a sense of relaxation. So where the application for this is where you see in general cancer pain or musculoskeletal pain. So in those settings, this can definitely be elements to help you improve the coping of pain, it's almost in the realm of self-care. So patients can potentially do that at home. However, I would say the evidence still very low. So the quality of evidence we give is a low quality of evidence and weak strength of recommendation. Although this therapy is very intuitive, they cause relaxation, which should help with pain. But I would say they by themselves may not be... the primary mode to manage pain, but rather than improve the coping of pain. Dr. Lee: And let's shift gears a little bit to other techniques. One that was mentioned was music therapy. And of course, a lot of people listen to music on the radio or on the way to work. Can you talk about  what is music therapy? Is that the same as just turning on the radio, and where can that be helpful for pain management?   Dr. Mao: So I'm so glad you're asking this question because music therapy is not just music. Music therapy is working with a specialized trained therapist to use music as an avenue to allow patients to develop a very meaningful therapeutic report to induce relaxation, to manage specific physical and emotional symptoms such as pain, depressive symptoms, anxiety. So often, you know, either through playing an instrument, creating sounds, and sometimes by passive listening and passive relaxation. So it's a very sort of an involved process. Where I think there are currently some weak levels of evidence is music therapy for post-operative for surgical pain. That's where there are some research, but because of the trial, the sample size and the control, so unfortunately we can only give a low quality of evidence and weak strength of recommendation. There's much more knowledge about the use of music therapy to reduce anxiety and depression. So, and often those psychological symptoms go hand in hand with a patient with pain. So I do think when we talk about pain management, we shouldn't be so reductionist to just think of a person with pain. Often you have pain, you have anxiety, then you feel depressed about the pain, right? So I think music therapy can play a role to improve the mental coping with pain. Dr. Lee: I think you bring up a really great point, Dr. Mao, about for patients who are being evaluated for pain to really work with their medical team to explore all the potential factors that might be contributing to the pain. Not only their cancer or the treatment, but their mood or how they're sleeping might play a factor. Dr. Mao: Rich, as you know, I'm an integrative medicine specialist. So when we work with patients, we really take a comprehensive history to really understand what are the symptoms. Often, I have never seen patients just presenting with one symptom, right? So then you'll understand their symptoms and needs and then help them to prioritize what matters the most for them and which therapies potentially have the biggest bang for the buck to improve the things they want to help the most. And then often those therapies will produce some, what I call the “side benefit,” say by improving pain, also improve your sleep, improve your anxiety. So the mechanism may be slightly different, and also patients may have different preference. Some people love yoga, other people would never try it. So you got to really, this is what the beauty is about integrative oncology, to give that choice and control back to the patients. But really, as physicians, we provide them with the evidence to help them to make informed decisions. Dr. Lee: And what do you think are the kind of key takeaway points a patient should think about based on these guidelines? Dr. Mao: I think the key takeaway is when you experience pain, don't just think about drugs. Really think about, there are evidence-based non-pharmacological interventions that can really potentially help you reduce pain, improve your emotional and physical coping with the pain. So talk to your doctors and nurses. Are there those therapies available in your cancer center or clinical practice? Or connect you with the qualified community providers and be a strong advocate for your own health. Dr. Lee: And for patients who really want to dive deep and learn more about these, where would you suggest they go to learn more about integrative therapies for cancer-related pain? Dr. Mao: Yeah, as a patient as well as a family member, it's really important to go to websites that are credible for reliable information. So, ASCO has Cancer.Net. It provides incredibly valuable information for patients and families impacted by cancer. American Cancer Society will be a good resource as well. National Cancer Institute also have monographs for integrative therapy, so those can be really valuable. Other places like a Society for Integrative Oncology website or Memorial Sloan Kettering Cancer Center website also have a lot of information about integrative therapies. Dr. Lee: So this has been wonderful. I really want to thank Dr. Mao for a great overview regarding the ASCO-SIO joint guidelines on pain management. And you mentioned a lot of great websites, including Cancer.Net, in which you can learn more about these guidelines as well as other therapies to help with your care. Dr. Mao: Dr. Lee, thank you so much for doing this really important podcast. I do think as one of the co-chairs for this committee, our group really aspired to use this set of ASCO-SIO clinical guidelines to make integrative therapies part of comprehensive pain management for patients impacted by cancer. And together, we can move closer to allow cancer patients to have lower symptom burden, high quality of life. Dr. Lee: I really congratulate you and Dr. Bruera for a job well done, co-chairing this really large effort. It took a lot of time. We're looking forward to additional guidelines coming out from ASCO and SIO looking at different symptoms. ASCO: Thank you, Dr. Lee and Dr. Mao. Learn more about integrative medicine at www.cancer.net/integrative. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.07.15.549144v1?rss=1 Authors: Duarte-Guterman, P., Skandalis, D. A., Merkl, A., Geissler, D. B., Ehret, G. Abstract: In most mammals, providing paternal care is not automatic. In house mice, experience with pups governs the extent and quality of paternal care. First-time fathers undergo a dramatic transition from ignoring or killing pups to caring for pups. The behavioural shift occurs together with changes in brain estrogen signalling as indicated by changes in estrogen receptor presence and distribution in multiple areas regulating olfaction, emotion, and motivation. Here, we report estrogen dynamics by altered local estrogen synthesis via changes in aromatase, a key enzyme catalysing the conversion of testosterone to estrogen. The amount of paternal experience (5 or 27 days) was associated with increased numbers of immunocytochemically-identified aromatase expressing cells in the medial and cortical amygdala, piriform cortex, and ventromedial hypothalamus. In the lateral septum, and to some extent in the medial preoptic area, parental experience increased aromatase only in fathers with 27 days of experience, and only in the right brain hemisphere, a new case of brain-functional lateralisation with experience. Nuclei/areas associated with maternal care (medial preoptic area, bed nucleus of stria terminalis, nucleus accumbens) exhibited a left-hemisphere advantage in aromatase expressing cells. This newly found lateralisation may contribute to the left-hemisphere dominant processing and perception of pup calls to release parental behaviour. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

In 1D Talks: Episode 31, Dr. Todd Lee - IFBB Pro, joins Joe and Justin to discuss bodybuilding, anabolics, testosterone, liquid T4, hormone health, family life, and funny opinions!1:10 - Introduction/How did Justin meet Todd4:39 - Ken Jackson6:30 - How did Justin meet Todd continued, and Todd working with different coaches12:50 - Hard working mentality in a prep15:40 - John's prep and peak week protocols16:24 - Todd's competition plans17:37 - Todd's cardio regiment20:20 - Circadian rhythms could be different for everyone23:45 - Todd's tips for better sleep27:20 - Tiktok's algorithm28:27 - Sunlight after waking up30:00 - Hot ball theory33:40 - T4 and growth hormone36:04 - Raloxifene37:20 - Aromatase inhibitors for breast cancer40:25 - Steroid pathways43:23 - How does Todd deal with erectile dysfunction 46:40 - Tren leading to higher prolactin50:35 - Hard to conduct studies on hormone intricacies 51:41 - ED54:13 - Todd using Melanotan 56:15 - Todd's protocol and thoughts for Ozempic 58:14 - Research on reps in reserve vs training to failure1:00:18 - Everybody demonizing steroids and the benefits of steroids1:00:04- Nandrolone only cycles1:06:30 - Justin's approach to steroids1:09:20 - Intermission1:10:53 - T4 and GH1:14:05 - T3- Follow Dr. Todd and Learn About His Services-  Subscribe to Dr. Todd on YouTube.- Hosted by Joe Miller and Justin Harris of 1st DetachmentSupport the show** DISCLAIMER **The content on this channel is for entertainment and educational purposes only. 1st Detachment does not provide, endorse, or promote specific medical providers. We do not make warranties to its accuracy, application, and completeness. Our guests share their opinions and views on a variety of complex topics. Always seek advice from qualified medical practitioners. Do not disregard medical advice or delay seeking medical treatment due to the information presented on this channel.Consult with a physician before taking any over-the-counter medications, supplements, or herbs. This channel does not endorse medications, vitamins, or herbs, nor do we condone the use of illegal drugs.Consistent with community guidelines, we do not glorify the use of illegal drugs or the consumption of drugs illegally. A qualified medical professional should make decisions with each patient's health profile, current prescriptions, and medical history in mind.

In this podcast, Adam Brufsky from the UPMC Hillman Cancer Center, Magee-Women's Hospital, University of Pittsburgh Medical Center in Pittsburgh, and Christopher Gallagher from the Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC discuss how real-world data in heterogeneous patient populations can complement clinical trial data in informing treatment decision making for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer. Specifically, their focus is on P-REALITY X, an observational retrospective analysis that was recently published in npj Breast Cancer.  This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-023-00968-4. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

This week we are continuing our mini-series on low testosterone (low T). Last week we covered clinical options to help replace testosterone, but there are many ways to boost your testosterone naturally. Today we'll go over our favorite natural ways to help boost your low T to increase your energy, control body fat distribution, and maintain muscle and bone growth. All this and more in less than 5 minutes. Does food affect testosterone? You don't have to be a nutritionist to know that our diets are important for overall health. Think back to the last time you overindulged in a big meal or fast food. As you finished your meal, you may have felt tired or sluggish. The food you eat should always make you feel your best so that you have the fuel to function properly — which includes the production and metabolism of hormones like testosterone.   There are many claims that certain foods can increase your testosterone levels. Some people believe that onions, garlic, ginger, shellfish, and fatty fish like tuna and salmon will help increase low T. Others believe that leafy green vegetables like spinach and kale, bananas and pomegranates, and eggs will help.  Why do people think that certain foods can boost low T? Because testosterone helps to maintain muscle and bone growth and helps with energy levels, the idea of eating certain foods to boost low T has emerged. What does the science say? Many factors can, in fact, affect testosterone levels, with diet being one of them. Not getting enough nutrients like magnesium, vitamin D, and zinc can indirectly influence testosterone levels.  It's important to remember that research has shown that a healthy diet and lifestyle might affect low T, but certain food probably won't increase your testosterone levels. You must have testosterone supplementation. However, you can use diet to potentially keep your testosterone levels from dropping. Eating a diet rich in protein, complex carbohydrates (e.g., oats, quinoa, legumes, sweet potato), and healthy fats (e.g., avocado and fatty fish like tuna and salmon) may help maintain your testosterone levels.   You can increase your vitamin D levels by eating fatty fish, spending more time in the sun, and taking supplements. Minimize your stress Easier said than done, right? Studies have shown that continued exposure to stress increases your levels of cortisol. We've discussed cortisol in our other podcasts. But as a refresher, cortisol is a hormone released into your bloodstream that causes an increase in your heart rate and blood pressure. It's your natural "fight or flight" response. However, over time, if your body experiences repeated stress, you may begin to feel tired, irritable, depressed, and even experience weight gain. Cortisol also helps your body break down fats and suppress inflammation. This elevated cortisol decreases testosterone production. Maintain a healthy weight  Extra belly fat has aromatase. Aromatase is an enzyme that converts testosterone into estrogen. And extra estrogen will trigger your body to make less testosterone. This is a nasty cycle where the more belly fat you accumulate, the less testosterone your body makes. Drink less alcohol Studies have shown that alcohol can decrease the enzyme responsible for testosterone production. Heavy drinking can increase cortisol levels, cause weight gain, and reduce testosterone production.  Get more sleep Studies have shown that as little as 1 week of sleep deprivation can lower testosterone levels by 10% to 15%.  You can find more information at pepties.com. That's peptides without the D. Where we are tying all the peptide information together.  Thanks again for listening to The Peptide Podcast. We love having you as part of our community. We hope you enjoyed the testosterone mini-series. If you love this podcast, please share it with your friends and family on social media. Have a happy, healthy week! Pro Tip We're huge advocates of using daily collagen peptide supplements in your routine to help with skin, nail, bone, and joint health. But what do you know about peptides for health and wellness? Giving yourself a peptide injection can be scary or confusing. But we've got you covered. Check out 6 tips to make peptide injections easier. And, make sure you have the supplies you'll need. This may include syringes, needles, alcohol pads, and a sharps container.

$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Potter sequence 1:40, Renal agenesis 2:40, Renal cysts 4:01, Autosomal dominant polycystic kidney disease (ADPKD) 4:59, Autosomal recessive polycystic kidney disease (ARPKD) 6:40, MCKD and JNPH 7:58, Tuberous sclerosis 8:19, Von Hippel Lindau 8:57, Horseshoe kidney 9:53, Ureteropelvic junction obstructions 10:34,  Voiding cystourethrography (VCUG) 11:10, Vesicoureteral reflux 12:00, Posterior urethral valves 11:21, Hypospadias 14:15, Epispadias and bladder-exstrophy-epispadias-complex (BEEC) 15:10, Prune Belly Syndrome 15:58, Disorders of sexual development 16:36, Ambiguous genitalia 17:39, Embryology of sex differentiation 20:11, Anti-Mullerian hormone 20:52, Testosterone 21:19, Dihydrotestosterone 21:50, 5a-reductase deficiency 22:04, Androgen insensitivity syndrome 22:21, Aromatase deficiency 23:29, Congenital adrenal hyperplasia 24:25, 21-Hydroxylase deficiency 26:35, Other causes of CAH 30:36, Kallman syndrome 32:12, Semil-Lemil-Opitz syndrome 32:53, Practice questions 33:22

Thank you for joining us for our 2nd Cabral HouseCall of the weekend! I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Anonymous: Hi Dr Cabral, thank you for all you do and for your amazing podcasts, you are a wealth of knowledge and I trust your word before anyone else!! My question is about sodium. I get really dry skin mostly on my face when I have a very small amount of salt. Is this a gut issue like candida or yeast overgrowth, why would this be happening so much later in life? I'm a male, 43 years of age and I'm in pretty good health overall. I never had an issue with salt when I was younger, but now my nose, cheeks and sometimes hands get really really dry. I predominantly have salt only on the weekends, and whether its celtic or himalayan and maybe a cheat meal from a restaurant, it just seems to overloaded my body. I always keep up with my water throughout the day so I am hydrated as well. Any help with this is greatly appreciated, keep up the fantastic work!!!   Anonymous: Hi Dr. Cabral thank you for all you do and for putting out these podcasts daily. They're highly informative and I'm learning new things everyday!! My question is about bcaa's. I know you've talked about them before but I was just wondering if when working out or lifting weights, a person can have 3-5 grams in water during the session to keep the body anabolic and not tap into muscle as a fuel source? Ive heard that the leucine in bcaa's, if your having it every 3-4 hours throughout the day (especially if your not having any fish or meat with your meal) will basically flip an internal switch to keep you in a anabolic state so you don't slip into catabolism and you can keep building muscle. I know we are supposed to have half our body weight in protein a day, so would this go against that and up your protein intake too much? Thank you again for all you do!   Kelsey: I'm wondering the best approach to managing weight gain and inflammation and overall feeling better while taking an aromatase inhibitor.   Luciana: Dr. Cabral, I have a severe case of keloid scars. I have done multiple surgeries to remove them, but it keeps coming back. My last surgery was 2 years ago to remove two very large scars from my back and shoulder. After the surgery we followed up with radiation, compression, and steroid shots. I've been battling this since I was in 4th grade and have tried everything modern medicine has to offer. Yesterday I went to my doctor to get more steroid shots and he said I can't get them anymore because the skin is too thin. The scar is getting wider because of the tension in the shoulder. I've asked Naturopathic doctors before, but they didn't know how to help me. I've been following your work for the last few months and I'm getting ready to start the 21 day detox this weekend. Modern medicine claims that keloid scars are genetic, even though I'm the only one in my family who has it. I've always asked why I've only start developing them after age 10. Have you threated any patients with the same condition? What would your recommendation be? Should I setup an online consultation with you so we can further discuss the matter? Thank you for your time, Luciana   Alexis: Hello Dr Cabral, I'm in IHP2 and grateful for all you do. I was on the mend from Covid and 2 days later I woke with full body severe nerve pain. Then full body numbness & no longer able to walk. Diagnosed as Transverse Myelitis and positive for HHV6 and MOG. As a child I had JRA and EBV (then was fine!) and later had issues arise as an adult like: shingles, rashes, vertigo, food sensitivities. I worked with someone to get rid of Cdiff and Giardia. I've sealed and healed my gut a ton. But I must still have a higher viral load and/or other remaining issues, and this current virus attacked my nerves? What is the root?! I believe I can heal and I will! Any guidance on steps… greatly appreciated in this time of need, thank you   Tonya: Hello. My son has encopresis. He was diagnosed when he was 3 and now he is 10. For years the doctors said Miralax was the answer. Last year I decided enough was enough and quit the miralax. I hired a nutritionist and we did a food sensitivities test. Turns out he is allergic to dairy, gluten, soy, egg whites, peanuts, & tilapia. I searched your podcasts and found 1 other where you also suggested other testing so next we will do the stool test and so on. However, Ive also heard you mention a 5 day intestinal cleanse. And I was wondering if we could do this? Would this also work as a "Miralax"? Currently we are doing aloe vera juice and magnesium as well as a major diet change (that has been going great)! Thank you so much for everything!!   Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/2417 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!

In this episode, we review the high-yield topic of Pituitary Physiology from the Endocrine section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. In the Research Round Up series, ASCO experts and members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field and explain what it means for people with cancer. In today's episode, our guests will discuss new research in multiple myeloma, breast cancer, and cancer in adults 60 and over that was presented at the 2022 ASCO Annual Meeting, held June 3-7. First, Dr. Sagar Lonial discusses a study on treatment for newly-diagnosed multiple myeloma in people under 65.   Dr. Lonial is a professor of Hematology and Medical Oncology at Winship Cancer Institute at Emory University, where he also serves as Department Chair. He is also the Cancer.Net Associate Editor for Myeloma. View Dr. Lonial's disclosures at Cancer.Net. Dr. Lonial: Hello, I'm Dr. Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia. And today I'm going to discuss one of the Plenary abstracts at ASCO 2022, which was the DETERMINATION study, again, presented at the ASCO Annual Meeting. For the sake of disclosure, I just want to make sure I list that I was an investigator on this study. I also have consulting relationships with Takeda, Celgene, BMS, Janssen, and other companies that have agents in the context of multiple myeloma. So the reason I want to talk about this study today is I think it's a really important study that was designed over a decade ago to really ask the question, with a really powerful induction regimen that uses what we now call the RVd regimen, lenalidomide with bortezomib and dexamethasone, do you really still need to have high-dose therapy and autologous transplant as part of the treatment approach? And so the trial was a very simple randomized trial that everybody received RVd induction. And then there was a randomization between early transplant and then going on to consolidation and continuous lenalidomide maintenance versus no transplant going on to consolidation and lenalidomide maintenance. So both arms actually received continuous lenalidomide maintenance, which is really one of the important endpoints of this study overall. And the reason I say that is there was a smaller study done in France a few years previous to this where patients only received 1 to 2 years of lenalidomide maintenance. And in that trial, clearly the use of transplant was better. And the remission duration for the group that received the transplant was about 48 months. So the question was, with continuous lenalidomide maintenance, can you make that longer? So randomized trial, over 600 patients were randomized between these 2 arms. And the follow-up now is somewhere around 7 years in total. And what was demonstrated both in the ASCO Annual Meeting as well as in the paper that came out at the same time in the New England Journal of Medicine was that the remission duration was clearly longer in the group that had the transplant than the group that did not, even with both arms receiving continuous lenalidomide maintenance. And it was almost 66 months in the group that received the transplant, 21 months longer, almost 2 years longer than the group that did not receive the transplant. And so I think this is really important because what it says is that even in an era of really good induction therapy, transplant continues to offer significant benefit in terms of progression-free survival. Now, the reason progression-free survival is so important in this study is that we know that no time is more sensitive for treatment of myeloma than that first time we treat the patient. And so prolonging that first remission is really important because the disease is at its most sensitive at that time point. Now, there were questions about overall survival. Should we see an overall survival benefit? And I'll tell you, A, this trial was never designed to measure an overall survival benefit. And, B, the median survival for myeloma patients is now between 10 and 15 years on average. And so with only 7 year follow-up, it seems to me unrealistic to expect this to have a survival benefit at this early time point. So rather than saying there's no difference in overall survival, I think it's a fair statement to say at the short follow-up we have, there is no difference in survival. But I actually don't think survival is the right endpoint for newly diagnosed myeloma trials in fit patients because we do have so many important treatments to discuss. Now, there was also discussion about adverse events. Obviously, the quality of life during the transplant dropped a little bit. Not a big surprise. That lasted about 2 to 3 weeks, and then quickly, by 3 months out, returned back to baseline for almost every patient in the study. Additionally, there was a concern about second primary malignancies. If you look at this data, it's really no different than what we saw in the French study. There was a slightly higher risk of second primary malignancy, but we know that this is the case not only in myeloma, but in patients who receive alkylate-based therapy. And despite that, the progression-free survival was 2 years longer in the group that received the transplant than the group that did not. So I think, in summary, this is really an important trial because there are many groups that are making the case that perhaps we don't need transplant in this modern era of myeloma therapy. And I think that it's important to recognize that what we're looking at are not short-term endpoints. We're not looking at early MRD (minimal residual disease) negativity. What we're looking at is really ultimate measurement of clinical benefit, which to me is prolonging that first remission as long as you can. And so this trial clearly demonstrates that for young, fit patients, transplant continues to offer significant benefit, almost 2 years of benefit with continuous lenalidomide maintenance. And while there's a push to say perhaps we can think about which patients may or may not need a transplant, honestly, as clinicians, we're not good enough to make that prediction. And what I think is really important is that we not lose sight of trying to prolong that first remission with the best tools that we have. And I think even in this modern era of 2022, high-dose therapy and autologous transplant continues to be one of those tools, and we want to use it to maximize the duration of that first remission. So thank you again for listening to this brief summary of the DETERMINATION trial presented at the 2022 ASCO Annual Meeting and published in the New England Journal of Medicine. ASCO: Next, Dr. Norah Lynn Henry discusses new treatment advances for people with metastatic breast cancer, as well as 2 studies in early-stage breast cancer. Dr. Henry is an Associate Professor in the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and is the Breast Oncology Disease Lead at the Rogel Cancer Center. She is also the Cancer.Net Associate Editor for Breast Cancer. View Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi. I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of updates in breast cancer from the 2022 ASCO Annual Meeting. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both metastatic and early-stage breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We typically treat those cancers first with antiestrogen treatments, which block estrogen or lower estrogen levels. Other breast cancers are called “HER2 positive.” These are often more aggressive cancers, but because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or very much HER2. These are called triple-negative breast cancer and are also often aggressive cancers. One of the biggest stories from the ASCO Annual Meeting was the results of the DESTINY-Breast04 trial. In this trial, researchers studied a type of medication called trastuzumab deruxtecan, which is also called Enhertu. This drug is a combination of the anti-HER2 antibody, trastuzumab, plus a chemotherapy drug, and the antibody targets the drug to the cancer sort of like a guided missile. Trastuzumab deruxtecan is currently routinely used to treat patients with metastatic HER2-positive breast cancer. Now, the interesting thing is there was already data from studies that suggested that this drug might also work against breast cancers that have some HER2 receptors on the surface of their cells, but not so many that they meet the true definition of being HER2 positive. For the DESTINY-04 study, patients' tumors had to have either 1+ or 2+ HER2, which some people called “HER2 low,” and could be either estrogen receptor positive or negative. Two thirds of the patients were treated with trastuzumab deruxtecan, and the other one-third were treated with 1 of 4 different standard chemo regimens that their physician thought was the best treatment option for them. Treatment with trastuzumab deruxtecan was shown to lengthen the time people were able to remain on treatment. Importantly, it was also shown to increase the overall survival of patients compared to standard chemotherapy by more than 6 months for patients with estrogen receptor-positive cancer and by more than 10 months for patients with estrogen receptor-negative cancer. Since this is a drug that we currently use to treat patients with other types of cancer, we actually know a lot about its side effects. One key toxicity is it can cause a very severe inflammation of the lungs in a very small subset of patients. So this is something that we have to watch for very carefully. Otherwise, it is a relatively well-tolerated drug, especially compared to standard chemotherapy. The main side effects are nausea and fatigue. Another clinical trial presented at ASCO called TROPiCS-02 also studied a drug that is currently used to treat a different type of breast cancer. In this case, the drug is sacituzumab govitecan, also called Trodelvy. It is also a combination of an antibody that is targeted against cancer cells plus a chemotherapy drug. Sacituzumab govitecan is currently approved to treat metastatic triple-negative breast cancer. In the TROPiCS-02 trial, however, it was tested to see how effective it is for treating hormone receptor-positive, HER2-negative metastatic breast cancer. All of the patients enrolled in this trial had already been treated with antihormone therapy medications as well as at least 2 chemotherapy regimens. Half of the patients were randomized to treatment with sacituzumab govitecan, and the other half were treated with 1 of 4 standard chemotherapy drugs that their physician thought was the best for them. Those patients who were treated with sacituzumab govitecan had a longer time on average that the treatment worked compared to those who received standard chemo. They also had improved quality of life based on responses that the participants themselves provided on questionnaires. Although the overall benefit was rather modest, this drug may represent a new treatment option for patients with hormone receptor-positive, HER2-negative metastatic breast cancer, although at this time it isn't yet approved for treatment of this type of breast cancer. Both of these are examples of being able to take drugs that have been shown to treat 1 type of cancer and potentially expand it so that they can be used to benefit more patients with breast cancer. These drugs are also being tested to see if they are beneficial for treating early-stage breast cancer. So we await more hopefully very exciting results in the future. To switch gears a little bit, I'll now talk about another study I found interesting. This one is in the setting of early-stage breast cancer. So typically, radiation therapy is recommended after lumpectomy since it reduces the likelihood of cancer returning in the breast. However, questions have arisen about how much benefit radiation is actually providing for some patients whose risk of having cancer return in the breast is really low to start with. Therefore, these patients may be at risk of the side effects of radiation as well as other risks, such as financial problems, without actually getting much benefit from the treatment. Therefore, this trial, called LUMINA, evaluated whether radiation therapy was beneficial after lumpectomy for patients who have small, low-risk breast cancers and no lymph node involvement. The trial included 500 women who were at least 55 years of age with invasive ductal cancers that were no more than 2 centimeters in size. They had to be estrogen receptor-positive, HER2-negative, either grade 1 or 2, and Ki-67 low. Everyone had to be planning to take antihormone therapy for at least 5 years. During the 5-year follow-up period, a total of 10 patients out of 500, about 2.3% of all patients, had their cancer return in the breast. The researchers therefore concluded that for patients with this type of very low-risk breast cancer, it is reasonable to omit radiation therapy and just take endocrine therapy. Similar results have previously been shown for patients over the age of 70 with small lymph node-negative low-risk cancers, but this trial expands that option to patients who are as young as 55. Finally, I will touch briefly on the updated results from the ABCSG-18 clinical trial. So this trial enrolled postmenopausal women with early-stage estrogen receptor-positive breast cancer who are being treated with aromatase inhibitor therapy. Aromatase inhibitors are known to cause reductions in bone density. This trial therefore evaluated a medication called denosumab, also called Prolia, which is used to treat osteoporosis. Participants were randomized to treatment every 6 months with either denosumab or a placebo. They found that the patients who were treated with denosumab were half as likely to have a bone fracture. Importantly, patients treated with denosumab also had an improvement in bone density despite taking the aromatase inhibitor medicine, whereas those who received placebo had a decrease in their bone density over time. The other very interesting thing from this study is that patients who received treatment with denosumab were less likely to have their breast cancer return or to develop a new cancer during the 8-year follow-up period. So it's actually already recommended that postmenopausal patients with all types of early-stage breast cancer consider treatment with a different type of bone strengthening medicine called a bisphosphonate as part of their breast cancer treatment. The goal is to further reduce their risk of cancer returning. These new results will now lead experts to debate whether to also include denosumab as a potential additional breast cancer treatment option, not just to help protect people's bone density. There were a lot of other research findings presented that were related to treatment for both early-stage and metastatic breast cancer at the meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, and we eagerly await the results of large, randomized trials so that the drugs that work can be used to care for patients with breast cancer. But for now, that's it for this quick summary of important research from the 2022 ASCO Annual Meeting. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. Finally, Dr. Shakira Grant discusses 3 studies that looked at cancer in people 60 or older. This field is also known as geriatric oncology. Dr. Grant is an Assistant Professor in the Divisions of Hematology and Geriatric Medicine at the University of North Carolina at Chapel Hill and a board-certified Geriatric Hematologist/Oncologist. View Dr. Grant's disclosures at Cancer.Net. Dr. Grant: Hi, everyone. I am Dr. Shakira Grant. And I'm an assistant professor at the University of North Carolina at Chapel Hill. I'm also a clinician scientist with a focus on social disparities and how they influence the health and aging of older adults with cancer, primarily multiple myeloma. And for today's talk, I have no relevant conflicts of interest to disclose. It's such a pleasure to be able to talk today about the ASCO 2022 geriatric oncology and presenting key studies, which I believe were really practice-changing or really set up the foundation for informing future research directions. And to start us off, I wanted to start us with abstract 12012 by Dr. Mackenzie Fowler. And this was presented based on the University of Alabama at Birmingham's actual research group. And the title of their presentation was “Rural-Urban Disparities in Geriatric Assessment Impairments and Mortality Among Older Adults with Cancer.” And this was the result of a large registry study, predominantly patients with gastrointestinal cancer-- so cancers such as liver cancer, colon cancer. And what the authors really wanted to do here was to explore if whether or not living in a rural location, for example, is associated with having an impairment based on what people report in their ability to function at home, their quality of life. And they also wanted to see whether or not where you live, meaning a rural location, whether that can be associated with how long you are expected to live or your overall survival. So this was really a study that took patients who were truly older. There were patients who were above the age of 60. As I mentioned, these were patients predominantly with cancers of the liver, the colon, and the pancreas. And patients completed a baseline, what we call a geriatric assessment, to try to assess their overall or global health. And on these assessments, patients are asked questions about how they would rate their physical function and their quality of life. And what the authors found here is that in general, when patients lived in rural areas, this was associated with patients self-reporting more functional deficits, meaning that they reported that they had impairments in the ability to function at home from a physical perspective. They also had impairments in quality of life—so how you rate your general life and how you're doing from a day-to-day basis. And this was impaired if you lived in a rural residence. And then, importantly, this study also showed that living in a rural location—and, again, this study was centered in Alabama—that that was also associated with a reduced overall survival, meaning that people were found in rural areas to live a shorter life with these cancers compared to those who live in non-rural places or, as we call it, urban. And I think why I chose this particular study is because it's one of the first studies using a large data set of almost 1,000 patients that they have enrolled and really looking at the idea of the physical environment, so where a person lives, and how that really interacts with everything else to influence the health of an individual. And this study, I believe, really lays the foundation for an area of work in geriatric oncology where we are moving away from just thinking about the older adult, but we're also thinking about the older adult and the other identities. So we're really considering the sociocultural influence. So we think about race. We think about socioeconomic status, income. But now, we're also including the physical environment. And that is where people are living and spending the majority of their time. And that is in this study classified as rural-urban residency. So for this study, overall, I would say that this is really moving the field forward in a direction where we're moving away from just looking at just older adults, but we're thinking about older adults and all of the other stressors that they face, especially when they live in the community and how that impacts their health. The next study that I wanted to highlight was a study that was performed by Dr. Heidi Klepin at Atrium Health, Wake Forest Baptist. And this was a study that looked at evaluating the association between an electronic health record-embedded frailty measure and survival among patients with cancer. Again, this was an older adult population. It was just over 500 patients involved, and patients were over the age of 65. They had a new diagnosis of the most common cancers, which are lung cancer, colon cancer, and breast cancer. And the good thing about this particular study is that it sought to use data that is readily captured in the electronic health record to characterize a patient as fit, prefrail, and frail. So why is that important for the geriatric oncology community and even beyond is when we're dealing with older adults, we're always thinking about ways in which we can actually characterize their fitness and their ability to hence tolerate their therapies, being chemotherapy, and how likely they are to die if they're having these functional impairments. And so importantly, what this study showed was that in their sample, they found that up to 17% of people were characterized as frail using this index. And the significance of this finding is that when they looked at how long people were likely to live with these cancers, breaking it down according to if you were fit, prefrail, or frail, those who were frail had the shortest overall survival. So it means the time from which they were diagnosed until they die was much shorter than any of the other categories. And that equated to a difference between those who were fit and those who were prefrail of 10 months for those who were frail for overall survival and more than 54 months for those who were actually considered to be fit. So this is really, really important because what we are seeing is that if you are really fit, you are living on average with these cancers—the overall survival, at least for their institution, was more than 54 months. But then as you move across that spectrum of fitness, we're actually seeing that your survival decreases significantly. And so why is this important? So this is important because it's one of the first studies that is actually looking to operationalize the frailty measure for us to be able to potentially use and adapt into other health systems using data that we already collect. So it's no longer burdensome on patients to try to fill out additional forms or for other staff to be involved and collect this data. And this data is showing us that there is an association with this particular frailty index and the ability to predict overall survival-- so, again, a critical study in the geriatric oncology population looking at patients with the 3 most common types of cancer, which are lung cancer, colon cancer, and breast cancer, and really showing us that there is a way potentially to operationalize how we characterize the fitness level of an older adult and then using that data not just to say, "Yes, this person is frail," but for us in real-time to see results where we can see that there is a significant difference in terms of overall survival. Importantly, this is going to be a study where we continue to watch closely the developments over the next few years, especially as the authors and the research team note that their next steps involve looking at how to study how these frailty measures, or the frailty scores that people get when they come in and they're at baseline, how this changes throughout the course of treatment. And that has a lot of implications because now, we have the potential to start thinking about using a frailty-adapted approach to caring for older adults with cancer. What that means is when you're getting your treatment and we are following these scores, as we see things changing, this may be an indicator to us that, "Hey, we need to make some modifications in response to these frailty measures to make sure that our older adult population is able to tolerate their chemotherapies and have maximum benefit while also enjoying a good quality of life." So finally, I want to highlight this third study. And this was a study that was presented by Dr. Etienne Brain. And. Dr. Etienne Brain was also this year's B.J. Kennedy Award recipient. And each year ASCO recognizes the B.J. Kennedy Award recipient as an outstanding investigator who has made significant contributions in the area of research and clinical care of older adults with cancer. In this particular study, Dr. Etienne presented on behalf of his team the final results from a study that was looking at using endocrine therapy with or without chemotherapy for older adult women, so characterized as those who were over the age of 70, with a diagnosis of estrogen receptor-positive, HER2-negative breast cancer. And the importance for this study is that the question they sought to examine was whether or not patients who are in this age range still derive a benefit from receiving chemotherapy in addition to endocrine therapy. And what this study really showed is that there was no survival difference. Meaning when they looked at the data for 4 years, those who got chemotherapy plus endocrine therapy lived just as long as those who also just got endocrine therapy alone. And why this is important is because when you think about giving chemotherapy to an older adult population, as oncologists, we are always weighing the risks and the benefits associated with treatment. So we're always thinking about how tolerable is this drug likely to be? We want to minimize side effects because, at the end of the day, our goal is to treat the cancer, but we also want to focus in on the outcomes that matter most to the older adult population. And in general, these are things like maintaining your mobility, maintaining your mentation, maintaining good quality of life. And so we really want to make sure that we're balancing those risks. And this is why this particular study showing that with chemotherapy or without chemotherapy added to endocrine therapy, there seems to be no survival difference. This could be a way in which we move the field forward in thinking about a select group of patients with breast cancer and whether or not those patients truly need that extra toxicity or burden associated with using chemotherapy or whether endocrine therapy is enough. So with that, I will say across these 3 studies, even though they study different things-- we saw 1 study that looked at the intersectionality between older adults in terms of their chronological age but now starting to examine the influence of physical or social context and how that influences the health and outcomes for individuals with primarily gastrointestinal cancer. We also looked at the development of an electronic frailty index in patients with 3 most common solid tumors - lung cancer, colon, and breast cancer - and found that by using this frailty index collecting readily available data, that there was an association with predicting overall survival. And we saw that those who were characterized as frail had one of the shortest overall survivals. And then finally, in this study, looking at endocrine therapy alone versus chemotherapy and endocrine therapy, we saw that there was no survival difference again in an older adult population. And so what we are seeing here is a theme emerging as the importance of comprehensive evaluations of older adults and the importance also of these measures, when integrated across the research continuum, that they are useful in terms of predictive prognostic abilities and really lay the foundation for future research. So with that, I want to thank you for your time and thank you for listening. ASCO: Thank you, Dr. Grant. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

After breast cancer, there's a long list of things that contribute to fatigue,  -Chemically induced menopause  -Aromatase inhibitors  -Radiation treatments  -etc…  But how often have you considered that your emotions may be contributing to your fatigue?  Intense emotions including fear and anger create a physical response in the body that uses a lot of energy.  So, why is it so hard to let go of the thoughts that create those emotions and keep you in emotional pain in addition to undermining your physical health?  Holding onto intense emotions has been shown to contribute to depression, anxiety, heart disease, poor mental health, and more.  In this episode, I'll tell you about three of the most common thoughts I see, and experience, that create resistance when it comes to letting go of negative emotions and what you can do to move beyond those thoughts and closer to joy.    Referred to in this episode:  Better Than Before Breast Cancer Life Coaching Membership  Your High-Intensity Feelings May Be Tiring You Out 

Dr. Kyle Gillett has a unique approach to patient care using his six pillars of health: exercise, diet, sleep, stress, sunshine, and spirit. His expertise and teaching style are highly regarded in the integrative and functional medicine industry.  Dr. Gillet continues to make a name for himself in national media by forwarding the concepts of personalized medicine. Although he is an expert in many fields, in this episode we focus on male hormones.     Listen in as we discuss Dr. Gillett's pillars of health and how he uses them in practice. We also hear about his approach to balancing male hormones, the role of testing, and when to use testosterone replacement therapy (TRT).  Today on The Lab Report: 3:20 Kyle Gillett on family medicine and obesity medicine 8:00 The 6 Pillars of Health 10:45 The overall approach to male hormonal balance 12:20 When to reach for Testosterone Replacement Therapy (TRT) 19:35 Aromatase inhibitors and estrogen 22:05 TRT in females 24:35 The roll of the microbiome in hormonal health 28:40 Important nutrients for hormones 30:30 The Fireball         Additional Resources: Gillett Health Gillett Health on YouTube Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.   See omnystudio.com/listener for privacy information.

In this episode, we review the high-yield topic of Aromatase Deficiency from the Reproductive section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficialx Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Content with linksWebsite (MenElite) - tons of content hereInstagramYoutubeFree NewsletterProductsFix ED courseBecome an Alpha Energy Male course Hosted on Acast. See acast.com/privacy for more information.

Join us as we discuss an integrative approach to Polycystic Ovarian Syndrome (PCOS) with Dr. Felice Gersh. 10% of all women have PCOS, making it the most common female endocrine disorder and cause of female infertility in the world. Women with PCOS may suffer from acne, menstrual irregularity, infertility, obesity, autoimmune disease, diabetes, and heart disease. Traditionally, doctors treat symptoms one at a time, often with a new regime of pills for each symptom or an invasive surgery. This approach never addresses the underlying causes of PCOS so women are medicated but never healed. PCOS is not JUST a reproductive problem, there is a strong link between reproductive function and metabolic function. Dr. Gersh goes into great detail about how the two are related and how a woman with PCOS can start to make manageable changes in her life toward feeling better.   Episode Takeaways: What is Polycystic Ovarian Syndrome? Most common endocrine disorder in women Starts in childhood Symptoms in reproductive age women Ovaries malfunction because of hormonal imbalances High levels of antimalarial hormones  Aromatase not functioning well In young girls you may see images like PCOS however they are young and their ovaries are just learning to work. A woman more in their 20s is ok to diagnosis  A PCOS Diagnosis is now defined by  Ultrasound imaging where the follicles can be seen on the ovaries Menstrual irregularity  Fundamentally it's about estrogen deficiency and endocrine disruptors  Elevated Androgens - DHEA sulfate or high Testosterone  Male pattern baldness, systec acne, hair growth on the face PCOS is not JUST a reproductive problem There is a strong link between reproductive function and metabolic function Too overweight or too underweight run the risk of these issues Inflammation - chronic low level inflamed women, high rates of insulin resistance By age 40 these women are at higher risk for diabetes  There is a feeling of living with jetlag all the time Sleep problems  Struggle with melatonin production  Tools for improving PCOS Symptoms Food - you need more carbs than you think and you need to get the timing right If you can go Vegan for a little while that is helpful, if not, limit animal protein to just a few ounces Eat 9 servings of veggies a day, the body greatly benefits from the polyphenols, phytonutrients, fiber, and prebiotics in veggies  Have your biggest meal at breakfast, 1-2 hours after waking, smaller lunch, even smaller dinner. 13 hour fast between dinner and breakfast Try to eliminate snacking and stick to three meals this helps with insulin efficiency Have more Omega 3's via supplements, seafood, Krill, etc Organic soy (NOT processed soy)  No dairy  Sleep! Get your circadian rhythm back on track  Stop looking at screens 2 hrs before bed or use blue blocking glasses if you must be at a screen. Get bright light into your eyes first thing in the morning Either by sunlight or a a light box with 10,000 Lux Finish eating by 7pm A very small dose of melatonin before bed can sometimes be helpful .5 or 1 milligram is all you need (don't need it regularly)   Connect with Kiran and Dr. Beurkens: BetterBiome.com Instagram: better.biome Instagram: Microbiome Keynotes Facebook: Microbiome Keynotes Instagram: Dr. Nicole Instagram: Kiran Krishnan   Follow Dr. Gersh: Instagram Twitter Facebook

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.Read the full article:Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression

In this episode, Dr. Cam interviews one of our medical advisors at Maximus, Dr. Rand McClain. Dr. McClain earned his medical degree at Western University and completed his internship at the University of Southern California's Keck School of Medicine Residency Program (U.S.C. California Hospital) and has worked with some of the best and original innovators in Sports, Rejuvenative, Regenerative (“Anti-Aging”), Cosmetic and Family Medicine. Dr. McClain has dedicated over 35 years of his personal and professional life to studying nutrition, exercise, herbs, and supplements and is also a Master of Acupuncture and Traditional Chinese Medicine. They discuss the best ways for men to optimize their testosterone and why The Maximus King Protocol is superior, especially for younger men. Chapters 00:00 Intro 01:15 Why did you become a medical advisor at Maximus? 02:45 Testosterone 101 05:30 Testing your testosterone levels 08:40 Total vs Free Testosterone 12:25 Monitoring SHGB levels 13:50 Causes for the decline in men's testosterone 18:00 avoiding xenoestrogens 19:50 Primary vs Secondary Hypogonadism 22:45 SERMs and Enclomiphene 25:50 Why Enclomiphene is the best SERM for most guys 27:30 How Enclomiphene works 31:30 Enclomiphene vs TRT 33:00 Aromatase inhibitors 35:10 Why Enclomiphene has fewer side effects than TRT 40:00 The benefits of Enclomiphene 43:00 Testosterone and mood 44:20 Important vitamins for hormonal health 46:10 Why everyone needs to supplement Vitamin D 51:00 Best lifestyle choices to increase testosterone 55:30 Proper diets for optimal health 01:00:55 why cholesterol is important 01:04:20 Other important health markers 01:06:40 The future of healthcare 01:09:00 Why Enclomiphene is a better option for younger men 01:10:10 HCG vs Enclomiphene 01:13:40 Outro

My guest this week is Dr.Tami Meraglia. In this episode, Dr. Tami and I discuss her favorite hormone, testosterone. Not surprising since she is the author of The Hormone Secret. Testosterone is often a misunderstood and underappreciated hormone, especially for women. Did you know testosterone plays a really important role in women's health? Find out why as Dr. Tami walks us through many examples of women feeling much better when their testosterone levels were regulated. We discuss other important hormones involved in sleep, gut health, mental health. Optimizing hormones can help people to feel good enough to keep going on their healing journey.  Learn more about Dr.Tami on her website at https://drtami.com/ or reach out to her clinic by emailing support@drtami.com. Sponsor Offer:Oxford HealthSpan brings us Primeadine, the best formulated Spermidine supplement on the market!  What makes it stand out – it includes Spermine & Putrescine two other Polyamines that work hand in hand with Spermidine PLUS FOS, a prebiotic to feed the bacteria in your gut that make Spermidine!  I take Spermidine daily as do my family and my clients – it has become a solid member of my “foundation stack”.  Research has shown that Spermidine upregulates autophagy, helps the immune system to rejuvenate and it protects DNA – visible benefits experienced by myself and my clients include better sleep, hair, skin, and nails!   Sponsor offer: If you haven't tried it yet go to Primeadine.com and use promo code BIONAT15 to save 15% at https://oxfordhealthspan.com/products/best-spermidine-supplement Episode Takeaways: [06:20] How did Dr.Tami get to where she is today?.. [14:00] How much do hormones affect how people feel?.. [17:00] Are people too quick to get on TRT?.. [21:45] How is each patient's care addressed and customized? The three pillars of patient care… [32:42] Focused life force energy and meditation… [42:50] Is HRT dangerous? Do we need HRT or are there alternatives?.. [47:00] Thoughts on contraceptives that stop ovulation… [52:49] What are the key hormones that men have issues with besides testosterone?.. [54:00] How sleep affects hormones.. Are you a mouth breather?.. [61:50] Aromatase inhibitors and natural alternatives…   Follow Nat: Facebook Facebook Group  Instagram Work with Nat: Book Your 20 MInute Optimization Consult

Official Bodybuilding Podcast The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice. "Steroidspodcast@gmail.com" submit your questions for the next episode https://www.instagram.com/bodybuilderinthailand/ ULTIMATE GUIDE TO ROIDS #1 BOOK ON TRUTH IN THE HISTORY OF BODYBUILDING https://bodybuilderinthailand.com/ultimate-guide-to-roids/ Daily Text Msg Training $99/month and 1 Hour Phone Call Consult $59 Send Email to inquire about personal training to "Steroidspodcast@gmail.com" 0:00 New Years Resolution 2:23 New Years 2021 in Ukraine 3:07 Do Bodybuilders use "Bodybuilding Supplements" creatine etc. from places like GNC. are those products worthless or do they have any value. 7:15 Natty Protein Science 8:20 Creatine is dumb on steroids 11:40 Testosterone Dosages Cosmetic Effects 12:20 What Stack makes a Pro Bodybuilders Size 15:30 Getting big in a more professional manner 17:30 Unfortunately a lot of bodybuilders (most) do not get bloodwork done 21:42 PCT didn't work for this guy. He's having Low Testosterone symptoms months after (discussion) How the HPTA Axis works 25:40 Aromatase inhibitors increase natural testosterone output 27:09 Vitamin D Injections - How I do it 30:30 Obsessing about Ratio's between different steroids for example (high tren low test internet obsession) 32:20 Interesting toxicity information about trenbolone 34:00 Liver Supplements that Work 37:00 Trying to get a prescription for testosterone 41:15 Extreme PIP post injections pain and Inflammation on 1st Cycle 47:00 Pharmaceutical grade Testosterone Propionate does not hurt and does not cause much inflammation 48:04 Snoring and Sleep Apnea on Anabolic Steroids Side Effects 50:41 Women and Equipoise In Depth Discussion of Injectable Steroids in Women including HGH 1:01:00 Oral steroid advantages in women 1:06:00 High Blood Pressure and High Resting Heart Rate in Steroid User - Androgen Receptor Upregulation This Podcast is for entertainment and conversational purposes only. Serious Injury and Death can occur from utilizing chemical performance enhancement. This author does not support the use of illegal performance enhancing drugs. If any substances mentioned in this video are illegal in your country do not use them. The purpose of this podcast is not to glorify the use of PED's but to bring to light the reality of what athletes are doing privately. Consult a doctor before beginning any exercise or supplement routine. Do not take anything mentioned in this video as advice. It is simply conversation, not advice.

Besides 2-methoxy-17beta-estradiol, cell cycle arrest via chromatin deacetylation can mitigate cell proliferation by decreasing global transcription while promoting the expression of tumor suppressor genes like p16INK4a while DNA Damage Repair (DDR) from pro-inflammatory cytokine production from senescent cells and Th1 lymphocytes can inhibit commitment to mitosis and cytokinesis by generating the paracrine SASP paradigm. Refs. Am J Physiol Cell Physiol 2012;302:C1026-C1034 Steroids Volume 75, Issue 10, October 2010, Pages 625-631 Oncotarget. 2013 Oct; 4(10): 1552–1553 Cancer Metastasis Rev. 2020; 39(3): 681–709 --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message Support this podcast: https://anchor.fm/dr-daniel-j-guerra/support

This is the last block of the hormone therapy drugs. We go through the Aromatase inhibitors, Gonadotropin releasing agonists, and Gonadotropin releasing hormone antagonists.

Understanding what happens in the second week of your menstrual cycle. We discuss the role of Testosterone, and how it increases our libido. As well as, how to approach exercise and nutrition during this week of your cycle,  fasting, the urge to socialize, and supplementation.  Betty Hormones Sign-up: https://hellobetty.club/betty-hormones/ Thank you to our sponsors: Athletic Greens - athleticgreens.com/stephanieOrion Red Light Therapy - Use promo code STEPHANIE10 for 10% off - https://www.orionrlt.ca/?ref=StephanieLumen - Use promo code DRSTEPHANIE25 for $25 Dollars off - https://www.lumen.me/LMNT Electrolytes - FREE 7 flavor sample pack at http://drinklmnt.com/DrEstimaSome of the links above are affiliate links. Making a purchase through these links won't cost you anything (and in many cases give you a discount), but we will receive a small commission. This is an easy, free way of supporting the podcast. Thank you! Social: https://www.instagram.com/dr.stephanie.estimahttps://www.facebook.com/groups/betterwithdrstephanie Membership Site:https://hellobetty.club/  Episode Overview: 4:08 Introduction To Week 28:07 Testosterone, Sex Hormones & Libidio 11:02 Movement  14:28 Cardio 17:00 Ligaments 19:44 Carbohydrates 22:27 Fasting25:21 Socialization 28:56 Supplementation   More information about the book at The Betty Body Book Join the Betty Booty ChallengeJoin the Hello Betty Community here! 

Many of us know insulin as the hormone that regulates our blood sugar. We often think of its role in diabetes. However, insulin affects far more than glucose. Dr. Ben Bikman is a PhD researcher who has been studying insulin for many years. His latest book, Why We Get Sick, outlines how insulin resistance is at the root of chronic disease and ways to treat and prevent it. In this episode, we speak to Dr. Bikman about the mechanisms of insulin resistance, its far-reaching effects in chronic disease, and strategies to improve it. Today on The Lab Report: 2:20 Meet Dr. Bikman and learn why he focuses his research on insulin 8:35 Insulin and insulin resistance   13:55 Where in the body does insulin resistance start? 18:25 Hypertrophic vs. hyperplastic fat cells and the effects of free fatty acids 26:35 Signals that create hypertrophic vs. hyperplastic fat cells 28:45 Muscle-centric model of insulin resistance 32:15 Chronic diseases as they relate to insulin resistance 35:50 Aromatase activity in adipose tissue 37:25 The brain and Alzheimer's disease as ‘type 3 diabetes'? 41:50 Fasting, ketosis, and lifestyle strategies to combat insulin resistance 47:35 COVID-19, immunity, and metabolic defenses 50:40 The Fireball Additional Resources: Why We Get Sick Ceremides as modulators of cellular and whole-body metabolism Adipose Tissue as an Endocrine Organ Ketones Elicit Distinct Alterations in Adipose Mitochondrial Bioenergetics Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week's episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don't forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests. See omnystudio.com/listener for privacy information.

Though many men worry about producing too little testosterone, many deal with elevated estrogen. In either case, the physical and mental health effects can be the same. Natural compounds like chrysin may be part of a solution, as chrysin may act as an aromatase inhibitor, reducing the conversion of testosterone to estrogen. Research shows it offers numerous other health benefits as well. What is chrysin? Chrysin is a naturally occurring polyphenol. You can extract it from: honeypropolisbitter melonwild Himalayan pearpassionflowersilver lindensome types of geranium To date, research has focused on chrysin ingestion alone. Whether it would provide any topical benefit remains to be seen. Chrysin Health Benefits Though most people learn of chrysin as an aromatase inhibitor, it affects many other aspects of health as well. Aromatase inhibition Excess estrogen in men or women contributes to physique, performance, and health problems. Like low testosterone levels, in men, excess estrogen contributes to gynecomastia (a.k.a. moobs) and other female physical characteristics. It may also increase body fat storage in the arms and hips and compromise muscle growth. Excess estrogen contributes to breast cancer, endometriosis, and difficulty improving body composition, strength, and physical performance in women. Chrysin may reduce the conversion of testosterone to estrogen. Indole-3-carbinol (I3C) and diindolylmethane (DIM) are two other popular natural products that may reduce aromatization. While they seem to be effective in some people, they don't seem to do much for me. That prompted me to investigate chrysin. Periodically, I develop mild gynecomastia on the left side of my chest. It seems to coincide with increased sun exposure, which increases vitamin D and may drive up testosterone production, which may increase testosterone aromatization to estrogen. In some men, as total testosterone levels rise, some of that extra testosterone gets converted to estrogen and can lead to undesirable effects. For me, my left nipple gets sore and firm. In the winter, it seems to go away. Animal studies and in vitro research shows chrysin does act as an aromatase inhibitor. However, there's very little in vivo research at this point. That said, it is very safe, so I ordered some to experiment on my own. Unfortunately, some supplement companies include it in “testosterone-boosting supplements.” That's pretty misleading. Chrysin does not increase testosterone but may keep estrogen levels in check or even lower them. In some men, lower estrogen leads to the same physical and mental health benefits as raising testosterone. Read also: Irritable Male Syndrome, Andropause, and Reclaiming Your Manhood. Healthy inflammation levels Like other natural compounds, such as curcumin, quercetin, and omega-3 fatty acids, chrysin supports healthy inflammation levels.  Chrysin alleviates inflammation through inhibition of COX-2, prostaglandin-E2, histamine, NF-γB pathway, tumor necrosis factor- (TNF-) alpha, iNOS, and cytokines (interleukin-1β, interleukin-2, interleukin-6, and interleukin-12) and activation of peroxisome proliferator-activated factor γ (PPARγ).Joohee Jung, Emerging Utilization of Chrysin Using Nanoscale Modification Inflammation contributes to heart disease, cancer, allergies, cognitive dysfunction, and many other conditions. Of course, a big part of staying healthy is eating well, following a good exercise program, and getting sufficient sleep. Chrysin may support better inflammation levels, but you still need to control your diet and lifestyle. Cardiovascular health Chrysin may support heart health by slowing the progression of atherosclerosis. Inflammation contributes to plaque formation, and since chrysin supports healthier inflammation levels, it may slow plaque formation. In addition, like nattokinase, chrysin may reduce cholesterol oxidation.

1. Regulação da Produção de Testosterona Gonadotrofinas (Estimulada pela Noradrenalina e Leptina/Inibida pela Beta-Endorfina) LH (Principal regulador da produção de testosterona pelas Células de Leydig) FSH (Desenvolvimento do Testículo imaturo) A regulação por retroalimentação negativa exercida pela testosterona é mediada pela conversão local em 17b-estradiol produzido pela aromatase. Testosterona pode se ligar ao receptor androgênico ou ser convertida em Dihidrotestosterona ou em estradiol 2. A Testosterona é um hormônio que depende do colesterol Depois de formada, ela pode seguir dois caminhos, sendo convertida em estradiol (Hormônio Feminino) ou Di-hidrotestosterona (Androgênio mais potente). Quanto maior a taxa de gordura do homem, maior a conversão da testosterona em estradiol - Caracteres femininos 3. Metabolismo da Testosterona Transporte pelo plasma (SHBG e Albumina) Conversão em Estradiol Conversão em Dihidrotestosterona (falar dos alvos farmacológicos) 4. Efeitos da Testosterona: Diminuir a reabsorção óssea e aumentar o tempo de vida dos osteoblastos Efeito anabólico no músculo esquelético Inibe a captação de lipídeos e estimula a lipólise nos adipócitos Aumenta o metabolismo e a oxidação de lipídeos Aumenta o processamento da glicose 5. Fatores que influenciam produção de testosterona Inibe: Soja e Fitoestrogênios (https://www.instagram.com/p/CDTW5f_FX5p/?utm_source=ig_web_copy_link) Exercícios longos e extenuantes Estresse Dieta vegetariana LF (pela falta de zinco?) Dieta Low Fat (https://www.instagram.com/p/CN9nZ_dlhRV/?utm_source=ig_web_copy_link) Ingestão excessiva de fibras parece afetar a síntese de Testosterona (não aumenta excreção) Aumento de PUFA (Ou diminuição de MUFA e SFA) DHT diminui em Low Fat pela diminuição de Testosterona Estimula: Dieta Cetogênica (https://www.instagram.com/p/CCGKeq9lVMu/?utm_source=ig_web_copy_link) Dieta High Fat Baixa atividade da Aromatase

Many of us know insulin as the hormone that regulates our blood sugar. We often think of its role in diabetes. However, insulin affects far more than glucose. Dr. Ben Bikman is a PhD researcher who has been studying insulin for many years. His latest book, Why We Get Sick, outlines how insulin resistance is at the root of chronic disease and ways to treat and prevent it. In this episode, we speak to Dr. Bikman about the mechanisms of insulin resistance, its far-reaching effects in chronic disease, and strategies to improve it. Today on The Lab Report: 2:20 Meet Dr. Bikman and learn why he focuses his research on insulin 8:35 Insulin and insulin resistance   13:55 Where in the body does insulin resistance start? 18:25 Hypertrophic vs. hyperplastic fat cells and the effects of free fatty acids 26:35 Signals that create hypertrophic vs. hyperplastic fat cells 28:45 Muscle-centric model of insulin resistance 32:15 Chronic diseases as they relate to insulin resistance 35:50 Aromatase activity in adipose tissue 37:25 The brain and Alzheimer’s disease as ‘type 3 diabetes’? 41:50 Fasting, ketosis, and lifestyle strategies to combat insulin resistance 47:35 COVID-19, immunity, and metabolic defenses 50:40 The Fireball Additional Resources: Why We Get Sick Ceremides as modulators of cellular and whole-body metabolism Adipose Tissue as an Endocrine Organ Ketones Elicit Distinct Alterations in Adipose Mitochondrial Bioenergetics Subscribe, Rate, & Review The Lab Report Thanks for tuning in to this week’s episode of The Lab Report, presented by Genova Diagnostics, with your hosts Michael Chapman and Patti Devers. If you enjoyed this episode, please hit the subscribe button and give us a rating or leave a review. Don’t forget to visit our website, like us on Facebook, follow us on Twitter, Instagram, and LinkedIn. Email Patti and Michael with your most interesting and pressing questions on functional medicine: podcast@gdx.net. And, be sure to share your favorite Lab Report episodes with your friends and colleagues on social media to help others learn more about Genova and all things related to functional medicine and specialty lab testing. Disclaimer: The content and information shared in The Lab Report is for educational purposes only and should not be taken as medical advice. The views and opinions expressed in The Lab Report represent the opinions and views of Michael Chapman and Patti Devers and their guests.           See omnystudio.com/listener for privacy information.

Talk to a Dr. Berg Keto Consultant today and get the help you need on your journey (free consultation). Call 1-540-299-1557 with your questions about Keto, Intermittent Fasting, or the use of Dr. Berg products. Consultants are available Monday through Friday from 8 AM to 10 PM EST. Saturday & Sunday from 9 AM to 6 PM EST. USA Only. Get Dr. Berg's Veggie Solution today! • Flavored (Sweetened) - http://bit.ly/3nHbNTs • Plain (Unflavored) - http://bit.ly/3as0x9U Take Dr. Berg's Free Keto Mini-Course! In this podcast, I'm going to talk about why men who are overweight often have low testosterone. Your body can turn androgen—which includes testosterone—into estrogen with an enzyme called aromatase. If you have too much aromatase, you will develop an imbalance of too much estrogen and not enough androgen. If you have this problem, you may experience these signs of low testosterone: 1. Breast tissue 2. Depression 3. Anxiety 4. Decreased libido Aromatase is made in several different tissues throughout the body, including bone, brain, testicle, and fat tissue. The more fat you have in your body—both subcutaneous and visceral—the more aromatase you will have. In turn, you can develop low testosterone. High levels of estrogen can also block testosterone. To fix low testosterone, you have to lose weight. The best way to lose weight is to go on a healthy ketogenic diet and intermittent fasting plan. While you're losing weight, you can also use aromatase inhibitors as well as compounds that help build up testosterone. These include: • DIM (a concentrated cruciferous compound) • Stinging nettle root • Zinc Dr. Eric Berg DC Bio: Dr. Berg, 51 years of age is a chiropractor who specializes in weight loss through nutritional & natural methods. His private practice is located in Alexandria, Virginia. His clients include senior officials in the U.S. government & the Justice Department, ambassadors, medical doctors, high-level executives of prominent corporations, scientists, engineers, professors, and other clients from all walks of life. He is the author of The 7 Principles of Fat Burning. Dr. Berg's Website: http://bit.ly/37AV0fk Dr. Berg's Recipe Ideas: http://bit.ly/37FF6QR Dr. Berg's Reviews: http://bit.ly/3hkIvbb Dr. Berg's Shop: http://bit.ly/3mJcLxg Dr. Berg's Bio: http://bit.ly/3as2cfE Dr. Berg's Health Coach Training: http://bit.ly/3as2p2q Facebook: https://www.facebook.com/drericberg Messenger: https://www.messenger.com/t/drericberg Twitter: https://twitter.com/DrBergDC Instagram: https://www.instagram.com/drericberg/ YouTube: http://bit.ly/37DXt8C

See all the Healthcast at https://www.biobalancehealth.com/healthcast-blog/ This week we are looking at the concept of homeostasis. The question is how we get our bodies (in particular our hormones) to balance properly as we age. Men, in particular are the focus of this week's conversation. We know that as men age, they lose testosterone which needs to be replaced. What many men do not know, however, is that they also make estrogen and that estrogen too, needs to be replaced in the appropriate amount. The challenge is the balance point. How do we learn just how much of each hormone we need, and how do we obtain them? Those questions are the focus of our conversations this week.   An amazing adjunct to T pellet replacement for men: Anastrozole/Arimidex+T pellets. Anastrozole is an enzyme blocker, called Aromatase inhibitor (AI). It blocks the aromatase enzyme from converting Testosterone into estrogen. The side effects of oral anastrozole listed are not present in pellet-anastrozole. The dose is uniform and lasts 4-6 months, therefore there are no large swigs in T blood levels with pellet anastrozole. Anastrozole is one of three Estradiol/estrone blockers. It is the only one that is reversable (does not permanently damage the aromatase enzymes) and the only aromatase inhibitor enzyme blocker that causes weight loss rather than gain. This drug was designed to treat and prevent Breast Cancer. We now have expanded the uses for anastrozole and other AIs to treating endometrial cancer, man boobs, endometriosis, obesity, infertility agent for men, and to shrink fibroids in women.     At BioBalance Health, the focus of our work is to determine the appropriate amount of which hormones need to be restored and the appropriate amount so that a man (or woman) is able to live a healthy and independent life as they age. Any preexisting concerns regarding their health need to be addressed and the correct balance of hormones needs to be maintained.   Side Effects of oral anastrozole (Arimidex), not in pellet-anastrozole:             Arthritic pain in small joints             Blood clots             Headaches             Swelling  Patients who take Arimidex orally can have the above side effects but do not experience these side effects of Arimidex if they take it in pellets combined with testosterone. The purpose of using the anastrozole pellets in men is to stop the conversion of testosterone into estrogen.   High Estrogens in Men can be caused by: A genetic problem where a man has the genes to convert more T into estrone and estradiol than other men Aging increase T conversion into estrogens Obesity: fat tissue is where the T is converted into estrogen High alcohol intake Insulin resistance Adult onset diabetes, high carb intake   Men as they age begin to convert more of their testosterone into estrogen and this leads to fat around the belly and breasts and face. A man will get more- plump and less muscular. To avoid this problem, we want to restrict the conversion of testosterone into estrogen to the minimal amount that a man needs to be healthy. The excess leads to vulnerability to other diseases that we want to avoid.   This treatment was originally used on women to help prevent breast cancers. It was a case of serendipity that doctors began to use it in treating men, particularly young men who were suffering from being less masculine in appearance because of the fat tissues from estrogen. Many of these young men develop man boobs and are teased unmercifully as teen -agers. Doctors were trying to find a way to help them avoid this problem.   If either a woman or man are taking arimidex orally they tend to have side effects like headaches that can be avoided entirely if the arimidex is given along with the testosterone in a pellet that is injected in the abdomen. Once the ideal response occurs, then men can be put on a maintenance dose of testosterone and the balance of estrogen conversion is in the correct range, they can sometimes stop taking the arimidex. If the balance is correct, they do not develop side effects and they feel good.   Why are there concerns about high levels of estrogen in men as they age? Estrogen in men causes prostate enlargement. If you are obese and have a lot of fat your prostate will enlarge and increase the likelihood of your getting cancer. Obesity and diabetes can also increase your chances of getting Alzheimer's and of getting cancer. Men must work on their diet and exercise and take the correct hormone replacement in order to avoid these illnesses and be able to remain muscular and active as they age.   Dr. Maupin has been following the research of Dr. Rebecca Glaser, MD that has supported what she has been doing at BioBalance health for 15 years. In Dr. Gaser's research she finds that other uses of Anastrozole in men to consider are: Stimulate the production of testosterone in young men who still produce their own T Male infertility Treating man boobs Weight loss   The more estrogen a man makes the more likely he is to have emotional flooding and cry more easily. High estrogen causes weight gain, prostate enlargement, decreased sex drive, ED. Men who take testosterone by methods other than pellets, often develop side effects that cause them to be miserable and to develop some symptoms of diseases that we are trying to avoid. If you replace your lost testosterone with pellets you will avoid those diseases and feel better as you age! Dr. Maupin will put you on a diet, develop a personalized exercise program and maintain your correct hormone balances and you will be able to lose weight, regain your sexual drive, lose your man boobs, some of your belly fat, and be able to grow muscles to get yourself back into shape. If that sounds too good to be true, you need to make an appointment at BioBalance Health and discuss your options with Dr.'s Sullivan and Maupin. You will be glad you did!

Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD. Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia. Key Opinion Leader to Korean Health Industry Development Institute Previously held senior business development and management roles at IQVIA, EPS International and ICON. Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer. Bachelor of Pharmacy from University of Mumbai.

In today's episode, we are talking about some of the "unsealed" strategies Big Ag and Big Pharma try to sell us on an idea. Here are some of the links we talked about in this episode.Dr. Tyrone Hayes TedtalkEPA Gives Agribusiness Giant Syngenta a Pass on Pesticide Monitoring Due to Covid-19 ConcernsFull story of the Dr Elaine Ingham controversy over Klebsiella p.

Today I am asking Ken, founder of Matrix Hormones questions, rapid fire style. If you need a clinic, check out our discount section the the All Things Testosterone website.  Topics covered today: Ken's background Will HCG be available? Is HCG Necessary? Would testosterone survive a trip into the stratosphere? MCT based Cypionate Switching to a new provider Low daily dose of cialis Stopping TRT cold turkey E1 (estrone) vs E2 (estradiol) Aromatase inhibitor or nah? Backfilling Pregnenelone and DHEA or nah? Sub Q vs IM Free vs total testosterone/SHBG and Boron 

Jim Goetz and Dr. Mike Brandon of Functionised discuss the in's and out's of body fat, why you gain it, whats good about it, what's bad about it and how to remove excess. Woes of Fat Define fat- adipose, so body fat%, not bmi! Speaking white adipose here, not brown For men, a percentage of body fat greater than 25% defines obesity, with 21-25% being borderline. For women, over 33% defines obesity, with 31-33% being borderline. -other than being ugly, we get told to lose it, but why? Just to buy new clothes Physical Excess weight on joints, back, neck More difficult for correct posture which leads to more pain Hormones it effects- why they matter Leptin suppress hunger, when depleted increases obesity- Where does it come from/why does it stop Injections dont help. Ceiling for it and brain becomes resistant to it Does not increase leptin by decreasing food intake; rather, lack of leptin acts as a signal to increase food intake Obesity decreases sensitivity to it, so DM and obese have a harder time feeling full Aromatase- is released Converts test to estrogen- decreases metabolism, increases insulin resistance High estrogen issues Females- Homronal acne, depressed metabolism,irregular menstration, bloating, cold/itchy hands/feet, insomnia, headaches, low sex drive, increased breast and other cancer risks Males- gynecamastia, low sex drive, Erectile dsfunction, infertilaty Resistin- also released by epithelial cells, increased secretion with a high body fat percentage Directly increases insulin resistance- Increases production of LDL cholesterol Increases cardio vascular disease risk Appears that centralised/wastline adipose releases more than other locations Association with DMtype 2 and centralised obesity faster than booty fat Pro inflammatides- mainly from resistin Interlukin 1, 3, 6; tumor necrosis factor- Causes systemic long term inflammation, like food sensitivities too Inflammation basis for … Increases risk of rheumatoid conditions Neuro transmitters Serotonin is released with insulin secretion, mainly from carb diet which is VERY common in obesity. “Use too much” serotonin and we get a little depressed, eat more sugar to increase mood, becomes less effective so do more frequently Part of the addiction cycle of carby foods Leads to many more poor choices when depressed Serotonin and dopamine Decreased transporters, so it gets harder to use these happy hormones/endorphions Comorbidities- things that are increased risk and caused by or in part by obesity Heart disease DM- resistin, and poor life style habits Cancer- hormonal cancers more so, but increased of all cancers since others are inflammatory Stroke - better chance surviving it...but also getting it Homron imbalances- stated above GI issues - inflammation of bowel, and then colon cancer, Dementia- Healing time? Depression- serotonin burn out www.functionised.comwww.fitlabnj.com Facebook: @functionisedInstagram: @functionised

It has been well-researched and even well-documented that the inhibition of estrogen is detrimental and even dangerous to men’s health.    The problem is, we still have people and even doctors who are making their patients take aromatase inhibitors.    The majority of information on aromatase inhibition originates from bro science and the bodybuilding subculture. This is harmful in so many ways, and it is damaging to the biological system on so many levels. Why is blocking estrogen while on testosterone so harmful?    Why is this still such a problem in the clinical community? How is the inhibition of aromatase causing so many problems for bodybuilders?    In this episode, I’m joined by leading androgen researcher and Tier1 Health and Wellness Research Director, Dr. Scott Howell shares a presentation and gives his professional, expert opinion on why we’re harming men when we suppress their estrogen.     The body has a failsafe mechanism which is the aromatase enzyme. The benefits of TOT are modulated by estradiol. -Scott Howell   Three Takeaways  Any time the aromatase enzyme function is interfered with, the body’s normal adaptive hypertrophy is exacerbated.   Estradiol is neuro-protective and essential for the integrity survival of dopamine neurons and mood stabilization. It’s also essential and vitally protective of the immune and cardiovascular system. The side effects of estrogen should be managed outside of the estradiol. 3 Things You’ll Learn In This Episode  What actually happens to our biological tissue when we knock out the androgen receptor  Why blocking estrogen is actually the cause for many deaths in the bodybuilding community  The 6 forms of androgen toxicity   Guest Bio-  Scott Howell, Ph.D. is the Research Director of Tier 1 Health and Wellness, Center for Clinical Research. He is an epidemiologist, exercise physiologist and mechanical engineer with research interests in the long-term safety of therapeutic androgen use, endocrine disrupting chemicals exposure, and preventative medicine. For more information send an email to showell@tier1hw.com or call 423.417.1700

This episode of HealthLine with Dr. David Hancock (D.C., MS Human Nutrition, FIAMA, Clinical Nutritionist) originally aired on KYCA on August 10, 2019. Schedule an appointment with Dr. David Hancock at Hancock Healthcare in Prescott, AZ by calling 928-445-5607. Services offered include Gentle Chiropractic Adjustments, Allergy Elimination, Needle-Free Acupuncture, Cold Laser Therapy, Clinical Nutrition Plans, Massage Therapy, Vertigo Treatment, Brimhall Body Scan, and Weight Management. On the last Thursday of each month from 4-5:15pm we also offer a monthly class covering a wide range of topics for just $5. Find us on Instagram, Twitter, and Facebook. #HancockHealthcare #HealthLine --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/healthline/support

See all the Healthcast at https://www.biobalancehealth.com/healthcast-blog/ As we age heart attacks are a more real probability for many of us. Especially since we are now learning so much about the way that women experience heart attacks that we did not know until recently.  One of the pieces of knowledge that we have recently discovered is that the estrogen balance in women is of particular importance in determining the risk of cardiovascular disease. Historically estrogen was given a bad rap for increasing the risk of heart attack and breast cancer in women! What they have found is that IF estrogen is given to women non-orally it actually decreases the risk of both breast cancer and heart attacks. Men also need a level of estrogen to be healthy. As we age our testosterone reduces and our estrogen increases. The type of estrogen we get or make is the bad type: estrone. It is made in fat and it makes more fat. It is because of estrone that women have increased risks of breast cancer if they are obese.  Men over 50 who are making less testosterone and have low free testosterone they are making more estrone than they need. So they have to be given an enzyme called Arimidex. This helps keep testosterone levels high and it reduces or blocks the conversion of testosterone to estrogen. Arimidex is an aromatase inhibitor. By making this adjustment in women or men who have breast cancer it reduces the manufacture of estrogen in fat tissues.  Doctors have to think in terms of balancing estrogen with Arimidex because they have to watch both heart disease issues or possibilities and breast cancer issues.  It is a question of balancing risks and making healthy choices. There is a good type of estrogen called estradiol and a bad one called estrone. What doctors attempt to do is to suppress estrone and still provide estradiol. Part of the challenge for hormone specialists like Dr. Kathy Maupin is to get other doctors, in particular cardiologists to accept this understanding of the balance of risks between heart disease and breast cancer and trying to restore our hormone balances to those of our younger years. She is making progress with this one cardiologist at a time.  In order to establish the balance between the two types of estrogen, Dr. Maupin provides an Arimidex pill that we can take to reduce estrone production and maintain estriol. When this is given appropriately, it is a very safe drug to take and will help you be able to resist heart problems and to avoid breast cancer.  Please listen to this week's podcast and learn the things you need to know to help keep you healthy and vibrant as you age.

Have you ever noticed how the fat seem to get fatter and the skinny people always stay skinny? It got me wondering about this after I seen my really attractive friend get pregnant... She put on a ton of body fat and then after she delivered the body fat never went away and it got worse... I started wondering if there could be something linked to having the excess body fat that was causing here to not be able to lose the weigh tor something... Later on in my life when I got into nutrition and bodybuilding I learned about testosterone and estrogen... I learned that body fat produces Aromatase which converts testosterone into estrogen... This essentially means that body fat lower your testosterone... And low testosterone is linked to an increase in body fat... The more testosterone you have the lower you body fat will be naturally... And YES...women have testosterone too! just less of it... That's why women naturally have more body fat then men... This means that if you have a lot of excess body fat it will be easier to produce more body fat and very hard to start losing it and keep it off... The good news is once you start losing body fat it will get easier and easier to keep losing it. Sign up for the waiting list for my Internalize Weight Loss Course where we will help you to start getting the body fat off so you can finally have the body of your dreams: https://www.internalizeweightloss.com

Today we are demystifying TRT therapy with author and educator Jay Campbell.  Jay is the founder of the TRT Revolution which dives deep on the latest exogenous testosterone research through via social media, podcasts, articles and books.    In this episode Jay and Ben discuss their personal experiences with testosterone as well as other hormone altering pharmaceuticals.  Jay presents the latest cutting edge research that challenges the paradigm of what your protocol should be on TRT and much more!   Time Stamps   Jay’s spiritual journey ad the wisdom/knowledge he has learned along the way. [4:04] How did he get involved in the hormone optimization realm? [8:50] Do therapeutic ranges of testosterone increase systemic estrogen? [13:25] When are the estrogen levels too high or low for men? What are side effects? [19:07] How visceral fat leads to all disease + the importance of ‘intelligent’ training. [28:45] What are the negative implications of testosterone prostate? [35:33] Is there an optimal place to hold your testosterone? [38:38] The ‘lab coat’ god syndrome. [41:45] What are signs you are testosterone deficient? [44:25] What should you be doing to optimize testosterone naturally? [47:12] The stigmas surrounding TRT. [52:50] The importance of optimizing your thyroid + the dangers of AI’s. [54:45] How alcohol is the destroyer of worlds. [1:03:05] Why you must live your life with the avoidance of social media. [1:05:00] The PROPER delivery systems and injection cycles of testosterone. [1:06:48] His take of HCG (Human chorionic gonadotropin). [1:14:08] Featured Guest Jay Campbell (@trtrevolution) • Instagram/Twitter Website Podcast Related Links/Products Mentioned The Definitive Testosterone Replacement Therapy MANual: How to Optimize Your Testosterone For Lifelong Health And Happiness – Book by Jay Campbell The Dangers of Estrogen Inhibition in Men Utilizing TOT Estrogeneration: How Estrogenics Are Making You Fat, Sick, and Infertile – Book by Anthony G. Jay Infertility and the provision of infertility medical services in developing countries Estrogen In Men: Good, Bad, Indifferent? An Evidence-Based Review for Optimal Health w/Dr. Neal Rouzier Part 1 Aromatase inhibitors in men: effects and therapeutic options The Importance of Sleep & The Threat of Artificial Blue Light Exposure w/James Swanwick Digital Minimalism: Choosing a Focused Life in a Noisy World - Book by Cal Newport The Current State of Male Hormone Replacement Therapy w/Jim Meehan People Mentioned Dr. Robert Kominiarek Dr. Anthony G. Jay (@anthonygjay) • Instagram Joseph T. Cruise, M.D Chris Barakat, MS, ATC, CISSN (@christopher.barakat) • Instagram Dr. Jordan Shallow D.C (@the_muscle_doc) • Instagram Abraham Morgentaler, MD Dr. Neal Rouzier (@PMCHormoneDoc) | Twitter Keith Nichols MD (@DrKeithHRTMD) | Twitter James Swanwick (@jamesswanwick) • Instagram Jim Meehan, MD (@DocMeehan) · Twitter

In this show Dr. Berkson reviews the science and safety of testosterone therapy in some breast cancer survivors. Dr. Berkson walks you through the studies. You hear how and why testosterone (T) might be a safe answer for some breast cancer patients to improve quality of life and reduce rate of recurrence.  In this show you’ll learn: How maleness protects femaleness (how T protects breast tissue). The differences between estrogen receptor alpha and beta. All about 3β-Adiol. In both genders. How T protects prostate tissue. The shadow side and controversy of T. Aromatase enzymes. The Estrogen Quotient. The Testosterone Metabolic Profile. The ratios of metabolites of female hormones (estrogens) to male hormones (androgens) and how to test for these, and where to get the kits. Finally, you learn specific natural answers to improve these ratios and decrease risk of hormonally driven cancers.   Want testing kits? Go to DrLindseyBerkson.com Click on Products We Love And Click on Hormone Test Kits, you pay there and a kit is shipped out to you.

In this episode we finish up PCOS by discussing the management and long-term consequences.   feedback@obgyn.fm   Polycystic ovary syndrome: etiology, pathogenesis and diagnosis Combined oral contraceptives in the treatment of polycystic ovary syndrome Ovarian Suppression in Normal-Weight and Obese Women During Oral Contraceptive Use: A Randomized Controlled Trial Ovulation incidence with oral contraceptives: a literature review Shorter pill-free interval in combined oral contraceptives decreases follicular development Comparison of efficacy of metformin and oral contraceptive combination of ethinyl estradiol and drospirenone in polycystic ovary syndrome Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review Metformin, oral contraceptives or both to manage oligo-amenorrhea in adolescents with polycystic ovary syndrome? A clinical review Additive Effects of Insulin-Sensitizing and Anti-Androgen Treatment in Young, Nonobese Women with Hyperinsulinism, Hyperandrogenism, Dyslipidemia, and Anovulation Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials Aromatase inhibitors for subfertile women with polycystic ovary syndrome: summary of a Cochrane review Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis The Impact of Bariatric Surgery on Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society Body Composition Is Improved During 12 Months' Treatment With Metformin Alone or Combined With Oral Contraceptives Compared With Treatment With Oral Contraceptives in Polycystic Ovary Syndrome Influences of weight, body fat patterning and nutrition on the management of PCOS

In this hormone mini class I discuss my recent test, how testosterone can turn into estrogen and why that is your worst enemy.  

Dr Mamounas presents data at the San Antonio Breast Cancer Symposium 2016 about the impact of letrozole treatment up to, and beyond, 5 years on disease free survival of post-menopausal women with HR breast cancer who have completed previous adjuvant aromatase inhibitory therapy. From nearly 4000 patients enrolled, he describes a reduction in the that of distant recurrent disease and improvement in breast cancer free interval events, though notes that overall benefits on DFS did not meet statistical significance. Dr Mamounas also notes an elevated risk of thrombotic events after 2.5 for patients receiving letrozole past that point.

Dr Pruneri talks to ecancer at IFCPE 2017 about a clinical trial looking at the prevalence of the aromatase gene amplification.

Solidify your knowledge of osteoporosis and osteopenia in this discussion with Endocrinologists and osteoporosis guideline authors, Dr. Rachel Pessah-Pollack, and Dr. Dan Hurley from the American Association of Clinical Endocrinologists (AACE). Learn when to start therapy after an acute hip fracture, how to use bone turnover markers to assess fracture risk, more on how to dose calcium and vitamin D, and finally, we discuss the new American College of Physicians (ACP) guidelines and how they differ from the AACE guidelines on osteoporosis. For a more basic talk on osteoporosis check out episode #18 w/Dr. Pauline Camacho. Full show notes available at http://thecurbsiders.com/podcast Join our newsletter mailing list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Time Stamps 00:00 Intro 03:00 Picks of the week 07:31 Guest and topic intro 10:25 Rapid fire questions 14:45 Clinical Case and defining osteoporosis 17:00 FRAX score 20:35 Secondary evaluation for cause of bone loss 20:54 Bone turnover markers (telopeptides) 23:17 Alkaline phosphatase 26:30 Calcium and Vit D 29:35 Recap of teaching points so far 31:25 Antiresorptive versus anabolic therapy 32:40 Aromatase inhibitors increase fracture risk 34:28 When to start therapy after fracture 35:44 Mechanism of action recombinant PTH 41:38 Vitamin D assay and dosing 46:53 Calcium intake, and formulations 49:45 Take home points 50:54 Recap and discussion of AACE vs ACP guidelines by The Curbsiders 59:42 Outro Tags: bone, osteoporosis, anabolic, osteopenia, vitamin D, calcium, fracture, density, AACE, guidelines, assistant, care, education, doctor, family, foam, foamed, health, hospitalist, hospital, internal, internist, nurse, medicine, medical, primary, physician, resident, student

Dr Goss presents at ASCO 2016, a Randomised​ Phase III Open Label Trial which looked at extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.

Dr Bartlett talks to ecancertv at SABCS 2015 about using HER2 status as a predictive marker for benefiting from treatment with an aromatase inhibitor (AI) versus tamoxifen based on data from a meta-analysis of more than 12,000 patients who participated in three landmark AI trials: ATAC (Arimidex, Tamoxifen, Alone or in Combination), BIG (Breast International Group) 1-98 and the TEAM (Tamoxifen Exemestane Adjuvant Multinational) studies. HER2 has been long proposed as a marker of endocrine resistance and data from the three landmark AI trials have suggested it might have a potential role in deciding if patients should be treated ‘upfront’ with an AI rather than tamoxifen. Alone, data from the trials were insufficient to determine if this was the case so a meta-analysis was performed. While improved outcomes were seen in women with HER2-negative tumours if they were treated with AIs rather than tamoxifen, the situation was less clear for women with HER2-positive tumours. The latter fared no better, or slightly worse, during AI treatment than those who received tamoxifen. Dr Bartlett explains what these findings might mean for clinical practice.

This week, Amol and Nathan discuss breast cancer and colorectal cancer: Two randomized control trials compared the aromatase inhibitor anastrozole to tamoxifen as adjuvant hormone therapy for postmenopausal women with ductal carcinoma in situ. Both trials were double blind and multi-centred, with one trial (NSABP B-35) enrolling North American patients and the other (IBIS-II DCIS) ... The post Together Again: Aromatase Inhibitor for DCIS and New Colorectal Cancer Screening Recommendations appeared first on Healthy Debate.

This week, Amol and Nathan discuss breast cancer and colorectal cancer: Two randomized control trials compared the aromatase inhibitor anastrozole to tamoxifen as adjuvant hormone therapy for postmenopausal women with ductal carcinoma in situ. Both trials were double blind and multi-centred, with one trial (NSABP B-35) enrolling North American patients and the other (IBIS-II DCIS) ...The post Together Again: Aromatase Inhibitor for DCIS and New Colorectal Cancer Screening Recommendations appeared first on Healthy Debate.

Norris Cotton Cancer Center Grand Rounds - Clinton Morgan, MD

This is a requested commentary regarding a concurrently-published manuscript which evaluated the utility of omega-2 fatty acids for the treatment of aromatase inhibitor-associated arthralgias.

What Causes Hormone Problems? In this episode, Dr. John Bartemus answers a listener's question regarding hormone issues and their causes.  This is a great episode to learn about the fundamental causes of hormone imbalances and how you can address them.  Before chasing after the sexy problems of thyroid dysfunction, pituitary dysfunction, etc, you would be smart to first check on the physiological fundamentals.  What are those?  Listen in to find out. www.johnbartemus.comwww.functionalmedicinedoctors.comwww.youtube.com/acceleratechirowww.facebook.com/functionalmedicinecharlottewww.twitter.com/functionmediclt  

Tue, 1 Jan 2013 12:00:00 +0100 https://epub.ub.uni-muenchen.de/21811/1/10_1159_000350777.pdf Kreienberg, Rolf; Nitz, Ulrike; Schulte, Hilde; Schmitt, Doris; Haidinger, Renate; Zaun, Silke; Windemuth-Kieselbach, Christi

David talks about the power of passionflower to calm our nervous system down and stop the aromatization of hormones into bad estrogens.

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer--analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Oncology Times Broadcast News Aromatase Inhibitor Better than Tamoxifen for Initial Adjuvant Therapy for HR- Positive Breast Cancer, But Compliance an Issue! Cornelis van de Velde at ECCO15-ESMO34 on the largest comparison of an aromatase inhibitor with tamoxifen as initial adjuvant therapy for patients with hormone receptor-positive breast cancer–analysis of results from the TEAM (Tamoxifen Exemestane Adjuvant Multinational) study reported at ECCO15-ESMO34.

Oncology Times Broadcast News For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival Charles Coombes at ECCO15-ESMO34 on the Intergroup Exemestane Study showing a big increase in survival for patients with early breast cancer randomized to have their adjuvant therapy switched to exemestane after 2-3 years of tamoxifen, compared with those who remained on tamoxifen for the entire 5 years of endocrine therapy.

The aim of the study was to further investigate the importance of local other and to detect possible differences of expression and localisation in poly- and monoovulatory species. Therefore ovaries of sexually mature gilts were collected at the local abattoir and follicles, which were determined to be in the follicular phase of oestrous cycle, ovarian stromal tissue and corpus luteum (CL) were prepared. In two experiments mRNA expression of gonadotropin receptors (LHR, FSHRregulatory factors during the final follicle growth in pig, to clarify relations among each), Aromatase (P450 Aro) and growth factors (fibroblast growth factor (FGF-1, FGF-2, FGF-7) and their receptors (FGFR-1IIIc, FGFR-2IIIb, FGFR-2IIIc), vascular endothelial growth factor (VEGF) and receptors (VEGFR-1, VEGFR-2), angiopoietin-tie-system (Angp-1, Angp-2, Tie-1, Tie-2) and nitric-oxid-synthase (eNOS, iNOS) were measured by qRT-PCR. An immunohistochemically determination and localisation was carried out for FGF-2, VEGF and VEGFR-1. Molecular size of FGF-2 was determined by westernblot. mRNA expression of the selected factors in pig total follicles and expression intensity in comparison to stromal tissue and CL was checked in experiment 1. Experiment 2 was concerned with the exact regulation of growth factors in the follicle compartments granulosa cells (GC) and theca interna (TI) during final follicular growth. A classification of follicles was performed according to follicular fluid oestradiol-17β (E2)-, progesterone and prostaglandin F2α content into four groups (2-3mm, 4-6mm, >7mm, post LH). Expression of FSHR decreased during follicle growth, while LHR and Aromatase increased. mRNA of FGF-family members was strongly expressed in stromal tissue. This was confirmed immunohistochemically by dominant localisation of FGF-2 protein in stromal cells. 18kDa and 22kDa isoforms of FGF-2 were overriding determined in stromal tissue. VEGF was located in GC and TI but not in stromal tissue. The receptor, VEGFR-1 was found in the endothelial- and smooth muscle cells of blood vessels. VEGF mRNA expression decreased after LH-peak. VEGFR-2 was upregulated in large follicles, VEGFR-1 after LH-peak. Angp-2/Angp-1 ratio was highest in small follicles, lowest in large follicles. After LH-peak the ratio rose again. Expression of eNOS was opposite with iNOS, which was downregulated in large follicles. FSH plays an important part in recruiting a folliclepool at time of luteolysis, while the further developing follicles become LH dependent. The number of LHR is an important selection criteria for the follicles. LH and E2 cause GC proliferation by mediators like FGF-7 and enhance angiogenesis by stimulating VEGF. While the follicle growth-up fast the pressure of oxygen in the follicular antrum decreases, whereby angiogenetic factors like VEGF and angiopoietins get stimulated and provide an adequate blood supply for the follicles. Activated by LH and VEGF eNOS is producing NO, which controls E2 synthesis and leads to a better blood flow in the TI through vasodilatation. Increasing E2 concentrations in large follicles stimulate Angp-1, which stabilise the now sufficient bloodvessel network in the TI. After the LH-peak Angp-2 destabilises the blood vessels, which is important for the process of ovulation and the succeeding angiogenesis in CL buildup. For follicle selection an important parameter seems to be the localisation of VEGF and FGF in the follicle. VEGF acts in the follicle and therefore follicles which express more VEGF and receptors have a developmental advantage. In cows this fact is suggested as one basic in selection of the one dominant follicle. FGF-2 in the pig is mainly expressed in stromal tissue and able to activate FGFR in the TI and increases angogenesis in a synergistic way with VEGF and its receptors. FGF-2 in stromal tissue consequently has influence on a few follicles and is maybe an important component in selection of follicles during final follicular growth in polyovulatory species.